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Abstract 
It is estimated that there are over 700,000 deaths annually worldwide due to multi-
drug resistant (MDR) bacterial infections and by 2050 this is predicted to rise to 10 
million. One of these MDR organisms is Acinetobacter baumannii, an opportunistic 
pathogen implicated in pneumonia, meningitis and septicaemia. It is especially difficult 
to treat due to its ability to become rapidly resistant to a wide range of antimicrobials 
and persist due to its ability to form biofilms. Biofilms are sessile communities of 
bacterial cells, attached to surfaces and embedded within a protective polysaccharide 
matrix, making them 10-1000 times more resistant than their planktonic form. 
Antimicrobial peptides (AMPs) are a diverse group of polypeptides that are present in 
nearly all living things as part of the innate immune system. They are being extensively 
researched as potential alternatives to classical antibiotics. The objective of this 
research project was to compare the bactericidal and biofilm activity of two synthetic 
nature inspired antimicrobial peptides, bicarinalin and BP100, with colistin sulphate. 
Colistin sulphate is an antimicrobial peptide, currently used as a last resort treatment 
of A. baumannii infections. 
The bacteriostatic and bactericidal effects of colistin sulphate, bicarinalin and BP100 on 
A. baumannii 19606 were assessed using microbiological assays and the consequences 
of peptide action was visualised on single cells of A. baumannii using atomic force 
microscopy (AFM). The changes in the roughness and area of the cell surface at 
increasing peptide concentrations were determined to quantify the effect of the three 
different peptides. 
The effect of the peptides on biofilm formation was investigated by determining the 
minimum biofilm inhibition concentration (MBIC) and on preformed biofilms using the 
biofilm removal assay. Peptide action on the biofilms was visualised by scanning 
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electron microscopy (SEM) and confocal laser scanning microscopy (CLSM). The 
nucleic acid stain SYTO9 was used with CLSM to visualise and quantify biofilm bio-
volume reduction at increasing concentrations of peptide. 
Bactericidal results showed concentrations of 0.5 µg/ml for colistin sulphate and 4 
µg/ml for both bicarinalin and BP100. Biofilm removal assay results highlighted that at 
higher concentrations, both bicarinalin and BP100 had significantly greater biofilm 
removal potential than colistin sulphate. At peptide concentrations of 1024 µg/ml, 
biofilm reduction was only circa 50% for colistin sulphate but 65% and 83% for the 
AMPs bicarinalin and BP100 respectively. At 2048 µg/ml, the highest concentration 
analysed, BP100 eradicated 95% of the biofilm, nearly twice that of colistin. 
AFM illustrated dramatic changes in cell size and membrane conformity when treated 
with peptides of concentrations at and above the MBC. SEM images showed the 
decrease in biofilm presence and cellular changes as peptide concentration increased. 
CLSM images and bio-volume quantification, with increasing peptide concentrations, 
further reinforced the evidence that bicarinalin and BP100 were more effective than 
colistin against A. baumannii biofilms at high concentrations. At a concentration of 
1000 µg/ml, bicarinalin and BP100 removed approximately 50-55% of the biofilms, 
twice as much as colistin, a trend consistent with the biofilm removal assay results. 
The results demonstrated the potential for AMPs as therapeutic alternatives to the 
currently used treatment against A. baumannii infections. Compared to colistin 
sulphate, bicarinalin and BP100 had generally better removal potential against A. 
baumannii biofilms. 
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1 Introduction 
1.1 Project Objectives 
By 2050, deaths due to antimicrobial resistant (AMR) infections are predicted to rise 
from 700,000 to 10 million a year worldwide. It is estimated that over the next 35 
years, 300 million people will die globally due to AMR infections (O’Neill, 2014). The 
abuse of currently used antimicrobials and the paucity of novel antimicrobials 
progressing successfully through clinical trials is a serious concern. The continuous 
evolution of bacterial resistance mechanisms have led to the prospect of patients dying 
from minor cuts, childbirth and elemental surgery within the next few decades 
(Rossolini et al., 2014). 
This project involves the opportunistic pathogen Acinetobacter baumannii responsible 
for various infections such as pneumonia, septicaemia, wound infections and 
meningitis (Maragakis and Perl, 2008). It is clinically important due to its ability to 
become rapidly resistant to a wide range of antimicrobials and also to persist on 
clinical surfaces by forming biofilms. Biofilms are structured consortia of bacteria 
embedded in a self-produced polymer matrix consisting of polysaccharide, protein and 
DNA, leading to a significantly increased tolerance to antimicrobials (Høiby et al., 
2010). 
The aim of the research project is to investigate the effectiveness of specific 
antimicrobial peptides (AMPs) against A. baumannii which may be useful alternatives 
to currently used antibiotics. AMPs are a diverse group of polypeptides that are present 
in nearly all living things as part of the innate immune system (Lakshmaiah et al., 
2015). They are being researched as potential alternatives to classical antibiotics due to 
their ability to kill multi-resistant (MDR) bacteria (Li et al., 2012). The project 
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examines the activity of two little researched antimicrobial peptides, bicarinalin and 
BP100. Bicarinalin is a peptide isolated from ant venom (Rifflet et al., 2012; Téné et al., 
2014), and BP100 is a synthetic hybrid of two peptides derived from bee venom and 
the haemolymph of a moth (Manzini et al., 2014; Alves et al., 2010). The effectiveness of 
these peptides was compared to the currently used antibiotic colistin sulphate which is 
commonly used as a last resort treatment for multi-drug resistant A. baumannii 
infections (Falagas et al., 2010; Potron et al., 2015).  
The methodology involved using microbiological assays and advanced visualisation 
techniques such as Scanning Electron Microscopy (SEM), Confocal Laser Scanning 
Microscopy (CLSM) and Atomic Force Microscopy (AFM). 
To investigate the effectiveness of bicarinalin and BP100 compared to colistin sulphate 
against planktonic A. baumannii cells, the minimum inhibitory concentration (MIC) and 
minimum bactericidal concentration (MBC) were determined. The consequence of 
interactions between each of the three antimicrobials and the bacterial cells was 
visualised at increasing concentrations (normalised to the MBC) using the AFM. The 
effects on the cell were also quantified by measuring the change in cell roughness and 
surface area at increasing concentrations for each antimicrobial. 
The minimum biofilm inhibitory concentration (MBIC) was determined to assess the 
ability of A. baumannii to form a biofilm in the presence of increasing concentrations of 
the three AMPs. The relative effectiveness of each peptide against preformed biofilms 
was quantitatively investigated at increasing peptide concentrations using the biofilm 
removal assay. The consequence of interactions between each of the antimicrobials and 
the A. baumannii biofilms was also visualised at increasing concentrations using the 
SEM and CLSM. The effects on the biofilms were also quantified, using CLSM, by 
measuring the bio-volume of a biofilm with the CLSM at increasing concentrations for 
each antimicrobial. 
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1.2 Project Outline 
The fundamental theory and a summary of previous research are described in Chapter 
2. The characteristics of A. baumannii, including the formation of its biofilms, are 
examined. The nature and antimicrobial mechanisms of the antibiotic, colistin sulphate 
and the two peptides, bicarinalin and BP100, are also discussed. The visualisation 
techniques used (AFM, SEM and CLSM) and the advantages and limitations of each 
microscope are compared.  
Chapter 3 discusses the materials and methods used. Tests were carried out to identify 
A. baumannii and its growth curve was determined to ensure reliable and practical 
assay techniques. Each experiment required a preliminary calibration to ensure a 
standard initial viable cell count of 5x105 colony forming units (CFU)/ml and hence 
consistent comparisons between the results. The methods and sample preparations are 
described in detail to permit further repeats of the experiments and independent 
validations of the results. The assay methods are explained to determine the MIC, MBC, 
to grow the biofilms and hence to determine the MBIC and biofilm removal with 
increasing peptide concentration. The preparation and visualisation techniques are 
described for the AFM, SEM and CLSM including the methodologies used to determine 
cell surface roughness, cell surface area and bio-volume of the biofilm. All experiments 
were repeated several times to achieve reliable results and the statistical analyses are 
also discussed. 
Chapter 4 describes the results of the microbiological assays and microscopic analysis. 
The MIC, MBC and MBIC are determined for the three AMPs. The results of the 
microscope visualisations are presented showing the effects on individual cells of A. 
baumannii and on A. baumannii biofilms when subjected to increasing peptide 
concentrations. For each antimicrobial, the cell surface area and roughness were 
quantified using AFM and biofilm bio-volume was quantified with CLSM. As the 
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measurements were made several times over a number of different experiments, the 
statistical confidence was indicated by error bars and statistical tests. 
Chapter 5 discusses the results and makes recommendations for further research.  
Further details of the identification techniques and results are included in the 
Appendix. 
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2 Fundamental Theory 
2.1 Antimicrobial Resistance 
Since the discovery of the antibiotic Penicillin by Alexander Fleming in 1928, healthcare 
and medicine have been revolutionised. Antibiotics have allowed complicated surgeries 
and treatment such as caesarean sections, chemotherapy, joint replacements and organ 
transplants to become commonplace in clinical practice. As a result, they have 
contributed to the increase of the average life span worldwide (Rossolini et al., 2014).  
However, antimicrobial resistant (AMR) infections currently claim at least 50,000 lives 
each year in Europe and USA and hundreds of thousands in other parts of the world. It 
is estimated that, over the next 35 years, 300 million people will die globally due to 
AMR infections. By the year 2050 there could be as many as 10 million deaths 
attributed to AMR each year worldwide (O’Neill, 2014). In financial terms, the 
consequences of AMR is also considerable. By 2050, the world’s Gross Domestic 
Product (GDP), is estimated to be reduced by 2-3.5%, equating to a loss of about £65 
trillion (O’Neill, 2014). 
 
2.1.1 The Current Dilemma 
One of the main problems in the treatment of bacterial infections is that, unlike most 
other drugs used in clinical treatment, antibiotics lose their efficacy over time. This 
means new antibiotic classes need to be discovered constantly as bacteria mutate to 
become resistant against the older classes. The period from the 1930s to the 1960s has 
been termed the ‘golden era’ of antibiotic research when most of the currently 
administered classes of antibiotics were discovered (Figure 2.1.1). From the 1970s to 
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2000 the antibiotic pipeline dried up. However, more recently twenty-two new 
antibiotics have been introduced associated with five new classes; linezolid (2000), 
daptomycin (2003), retapamulin (2007), fidaxomicin (2010) and bedaquiline (2012) 
(Figure 2.1.1). The introduction of bedaquiline was accelerated through clinical trials to 
help treat tuberculosis (Butler et al., 2013; Rossolini et al., 2014a).  
Although the launch of these recent novel antibiotic classes is a reason for short term 
optimism, they are all limited to the treatment of Gram-positive infections while it is 
the Gram-negative infections caused by pathogens such as Pseudomonas aeruginosa, 
Acinetobacter baumannii and those of the Enterobacteriaceae  family, that are in more 
urgent need of new therapies (Butler et al., 2013; Rossolini et al., 2014).  
 
 
Figure 2.1.1- Timeline of the Antibiotics from 1920s to present day (Lewis, 2012; Butler et al., 
2013) 
 
2.1.2 Origins of Antibiotic Resistance 
The appearance of multi-drug resistant (MDR) strains of bacteria arises through 
several different mechanisms such as alterations of the antibiotic target, changes in cell 
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permeability, efflux pumps within the cell membrane and the expression of resistance 
genes obtained from other cells by horizontal gene transfer (Rodríguez-Rojas et al., 
2013). 
Some antibiotics have been found to increase the mutation rate by promoting 
mutations within the bacteria. The induction of stress responses causes oxidative 
damage through the production of reactive oxygen species. This results in damage to 
cellular proteins, DNA and lipids which could lead to mutagenesis (Rodríguez-Rojas et 
al., 2013). 
 
2.1.3 Combating Antimicrobial Resistance 
As antimicrobial resistance becomes more problematic globally, it is vital to promote 
national and international policies to tackle the problem. It is essential to increase 
antimicrobial resistance awareness within the health and agricultural sectors and with 
the education of the general public. This would lead to a reduction in demand for 
antibiotic treatment, the unnecessary waste or discarding of antibiotics into the 
environment and reduction of antibiotic usage in agriculture and livestock (Rossolini et 
al., 2014). 
This increased awareness must also include healthcare staff and more stringent 
guidelines regarding prescription allocation by GPs. This will be helped by better 
diagnostics, reducing the dissemination of MDR organisms by surveillance of MDR 
strains, antimicrobial stewardship programs and infection control practices (Rossolini 
et al., 2014; O'Neill, 2015). Optimising the currently available antimicrobial therapy 
regimens with effective dosing, drug combinations and local rotating of drug usage will 
also help to control antimicrobial resistance (Rossolini et al., 2014). 
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Better focused financial incentives or benefits for pharmaceutical companies would 
encourage them to invest more into antibiotic discovery and development programs as 
well as suitable alternatives to antibiotics such as antimicrobial peptides, polymers, 
vaccines and phage therapy (O'Neill, 2015; Rossolini et al., 2014). In 2008, a change in 
the framework of phase III clinical trials by the US Food and Drug Administration 
(FDA), has made it more financially beneficial to consider investing in the development 
of new antibiotics whereas previously high costs and poor returns deterred many large 
pharmaceutical companies from conducting effective antibiotic research (Butler et al., 
2013).  
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2.2 Acinetobacter baumannii 
This research project investigated the effects of three antimicrobial peptides on one 
specific species of the bacterial genus Acinetobacter which is a cause of many deaths 
especially in hospital environments (Isa et al., 2014). 
Acinetobacter baumannii is an opportunistic Gram-negative, strictly aerobic, oxidase-
negative coccobacillus (Giamarellou et al., 2008; Abbott et al., 2013). Most 
Acinetobacter species are clinically irrelevant and ubiquitously found in the 
environment such as the normal microbiota of human skin, animals, water and soil 
(Abbott et al., 2013). However, A. baumannii is found almost exclusively in the hospital 
environment and is particularly prevalent in intensive care units and burns units; it has 
been reported to be responsible for between 2-10 % of all Gram-negative hospital 
infections (Isa et al., 2014). 
A. baumannii is is closely related phenotypically to other Acinetobacter species such as 
A. calcoaceticus, A. pittii and A. nosocomialis. As a result, it is very difficult to 
distinguish between the four species with phenotypic tests, so together they have been 
grouped together as the A. calcoaceticus-A. baumannii complex (Abbott et al., 2013; 
Toh et al., 2015). 
 
2.2.1 Clinical Relevance 
Acinetobacter baumannii is the most clinically relevant species of the Acinetobacter 
genus and, due to the emergence of MDR strains, it is recognised as a major 
opportunistic pathogen by its inclusion as a member of the ‘ESKAPE’ group. This group 
includes Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species. This 
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group causes the majority of hospital acquired infections and collectively requires new 
innovative practices to combat their pathogenesis, transmission and resistance 
(Boucher et al., 2009; Rice, 2008). 
A. baumannii is able to persist in the environment for long periods of time due to its 
ability to grow at a wide temperature and pH range, survive in both moist and dry 
conditions and exploit different energy sources. Environmental sources of outbreaks of 
A. baumannii such as curtains, door handles, mops and medical equipment have 
highlighted its ability to colonise and persist for long periods outside the human body 
(Isa et al., 2014; Maragakis and Perl, 2008). This persistence, along with intrinsic 
resistance to many antimicrobials, enables the pathogen to cause widespread epidemic 
infections within the hospital setting (Maragakis and Perl, 2008). 
A. baumannii has been implicated in a wide variety of hospital infections. Two with the 
highest mortality rates are ventilator associated pneumonia and septicaemia (Isa et al., 
2014). Other infections include meningitis, endocarditis, skin and soft tissue infections, 
urinary tract infections and wound infections (Maragakis and Perl, 2008; McConnell et 
al., 2013). 
Risk factors for A. baumannii infection include old age, use of mechanical ventilation 
during treatment, weakened immune system as a result of chemotherapy, prolonged 
hospital stay (especially in intensive care units), invasive procedures such as surgery 
and intravascular catheters, alcoholism, heavy smoking and underlying illnesses such 
as, diabetes mellitus, AIDS, and renal diseases (Isa et al., 2014; Maragakis and Perl, 
2008). 
 
11 
2.2.2 Virulence and Pathogenesis 
No one virulence factor has been found to be solely responsible for the clinical success 
of A. baumannii but a variety of virulence factors have been identified suggesting a 
multifactorial strategy for virulence. 
There are four main areas of virulence factors in A. baumannii: 
1. Outer Membrane proteins and Lipopolysaccharide 
2. Iron Acquisition Systems 
3. Lypolytic Enzymes 
4. Biofilm Formation 
 
It has been suggested that the outer membrane protein OmpA (Omp36) has roles in 
bacterial avoidance of immune systems such as complement mediated killing by 
interacting with inhibitors of the alternative complement pathway within the human 
body. The protein is believed to induce apoptosis in epithelial cells, through release of 
pro-apoptotic molecules such as cytochrome, and assisting in biofilm formation and 
surface motility (McConnell et al., 2013). 
A. baumannii is a Gram-negative organism which means its cell wall consists of a thin 
peptidoglycan layer and a protective outer membrane made up of phospholipids and 
lipoproteins as shown in Figure 2.2.1 (Silhavy et al., 2010; Cabeen and Jacobs-Wagner, 
2005). 
The lipopolysaccharide (LPS) is the main constituent of the outer leaflet of the outer cell 
membrane and consists of three components: O-antigen repeats and core 
oligosaccharides anchored to the phospholipid layer by the third component lipid A. 
Lipid A has been described as an endotoxin and shown to be a potent inducer of pro-
inflammatory cytokine expression in human monocytes (Isa et al., 2014). 
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Figure 2.2.1- Cell membrane and Gram negative wall of A. baumannii, showing the inner 
membrane, peptidoglycan layer, outer membrane and lipopolysaccharide leaflet 
components (Cabeen and Jacobs-Wagner, 2005).  
 
Iron acquisition systems are important virulence factors in A. baumannii by allowing it 
to survive and persist in limited iron conditions within the human host where most 
iron is sequestered by haemoglobin, transferrin and lactoferrin (Gordon and Wareham, 
2010; Gaddy et al., 2012; Eijkelkamp et al., 2011). 
Lypolytic enzymes such as phospholipases C and D, have been implicated in epithelial 
cell invasion by cleavage of phospholipids present in host cell membranes and survival 
in human serum (Isa et al., 2014; McConnell et al., 2013). 
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Biofilms can be defined as a structured consortium of bacteria, embedded in a self-
produced polymer matrix composed of polysaccharide, protein and DNA (Høiby et al., 
2010). This ability for A. baumannii to form biofilms is one of the main reasons why it 
is so prevalent in the clinical setting. The nature, formation and clinical relevance of A. 
baumannii biofilms are further explained in Section 2.3. 
 
2.2.3 Resistance Mechanisms 
The intrinsic resistance to certain antibiotics includes the presence of an outer 
membrane, which limits the access of antimicrobial to intracellular targets (Poole, 
2001), and the presence of certain enzymes. The acquisition of genes from transferable 
plasmids, transposons and integrons can lead to acquired resistance. The resistance 
mechanisms of A. baumannii fall into three categories:  
1. Antimicrobial-inactivating enzymes 
2. Changes in the antimicrobial target or cellular function due to mutations/gene 
transfer.  
3. Reduced access to bacterial targets 
 
Antimicrobial inactivating enzymes: A. baumannii contains genes, many of which are 
acquired by horizontal gene transfer, enabling it to synthesise enzymes that confer 
resistance against a wide range of antibiotics. β-lactams, such as penicillin, 
carbapenems and cephalosporins, are all related by the presence of the β-lactam ring 
(seen in penicillin in Figure 2.2.2). They exert their bactericidal activity by interfering 
with the cell wall and nucleic acid synthesis and inhibiting protein synthesis and 
metabolic pathways. A. baumannii is able to synthesise β-lactamases; enzymes that are 
able to cleave amide and ester groups conferring resistance against many of this 
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antibiotic group. Other genes acquired by A. baumannii encode for enzymes include 
(Camp & Tatum, 2010; Bonomo & Szabo, 2006; Maragakis & Perl, 2008):  
 AmpC cephalosporinases which confer resistance to broad spectrum 
cephalosporins. 
 Acetyltransferases, nucleotidyl-transferases and phosphotransferases that 
promote resistance to fluoroquinolones and members of the quinolone class. 
 Aminoglycosides, another class of antibiotic that includes gentamicin and 
amikacin. 
 
Figure 2.2.2- Diagram of the β-lactam ring within penicillin, (highlighted in red) (Zeng 
and Lin 2013). 
 
Mutations in genes within the bacteria, or acquired from other bacteria, can lead to 
alterations in antimicrobial bacterial targets, such as on the lipopolysaccharide layer of 
the outer membrane. This results in a reduced affinity for the antimicrobial target or an 
alteration in up-regulating cellular functions such as the production of efflux pumps. 
These pumps have the ability to actively expel β-lactams, aminoglycosides and 
quinolones from the cell (Camp and Tatum, 2010; Bonomo and Szabo, 2006; Maragakis 
and Perl, 2008). 
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Reduced access: outer membrane proteins (OMPs) and porins transport antimicrobial 
agents into the periplasmic space enabling them to access targets such as penicillin-
binding proteins. A loss of these transport proteins reduces the concentration of 
antimicrobials, such as carbapenems, entering the cell allowing β-lactamases to break 
down the antimicrobial (Camp and Tatum, 2010; Bonomo and Szabo, 2006.; Maragakis 
and Perl, 2008). 
 
2.2.4 Current Therapies 
Due to the increasing resistance rates of A. baumannii, treatment is becoming 
progressively more difficult. Current antibiotic treatments include the following: 
 The β-lactam class, carbapenems including meropenem and imipenem remain 
the treatment of choice.  
 β-lactamase inhibitors such as sulbactam are also used due to their potent 
activity against many A. baumannii strains.  
 Tigecycline, a glycylcycline antibiotic, has been used (Kassamali et al., 2015). 
 Colistin sulphate, a member of the polymyxin family, is used as a last resort 
treatment. Its effectiveness against A. baumannii was analysed in this research 
project and more information about its specific mechanism of action and A. 
baumannii’s mechanisms of resistance are further explained in Section 2.4.4 
(Maragakis and Perl, 2008). 
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2.3 Biofilms 
A biofilm can be defined as a structured consortium of bacteria embedded in a self-
produced polymer matrix consisting of polysaccharide, protein and DNA (Høiby et al., 
2010). Biofilms have been shown to have an increased tolerance to antimicrobials, of 
about 10-1000 times that of planktonic forms, although the cells themselves still show 
the same susceptibility when a biofilm is disrupted (Bjarnsholt, 2013; Høiby et al., 
2010; Mah et al., 2003).  
Biofilm growth can occur on biotic surfaces such as teeth and lungs and abiotic surfaces 
such as prosthetic joints, catheter and stents. As a result, biofilms have been implicated 
in persistent, chronic infections such as dental plaques, tuberculosis, otitis media, 
osteomyelitis (Høiby et al., 2010). 65-80% of all infections are thought to be biofilm 
related (Van Acker et al., 2014). 
 
2.3.1 Formation of Biofilms 
Biofilm formation is a multistage process consisting of four phases as summarised in 
Figure 2.3.1: 
1. Attachment of planktonic cells to an interface 
2. Formation of micro-colonies 
3. Maturation of the biofilm  
4. Detachment of cells from the biofilm  
 
For A. baumannii to initially adhere to a surface, it forms pili via the CsuA/BABCDE 
usher-chaperone assembly system; this is regulated by the two component BfmS/BfmR 
system with a sensor kinase encoded by bfmS and a response regulator encoded by 
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bfmR (Gaddy et al., 2009; Longo et al., 2014). The outer membrane protein, OmpA, is 
also thought to have a role in the attachment to certain surfaces (Longo et al., 2014). 
The extracellular polysaccharide poly-β-(1, 6)-N-actylglucosamine (PNAG), encoded 
from the pgaABCD operon, is thought to be involved in intercellular binding within the 
biofilm (Brossard and Campagnarl, 2012; Longo et al., 2014). 
 
 
Figure 2.3.1-The lifecycle of a biofilm. Four stages are illustrated: attachment, growth, 
maturation and dispersal (Donlan and Costerton, 2002; Høiby et al., 2010). 
 
The biofilm-associated protein (Bap) is believed to have a role in biofilm maturation 
and maintenance by increasing the cell surface hydrophobicity which is thought to help 
the binding to normal human bronchial, epithelial and neonatal keratinocyte cells. Bap 
is also necessary for the formation of water channels and 3D micro-colony formation 
(Brossard and Campagnarl, 2012; Lin, 2014). Cell to cell signalling in Gram-negative 
bacteria is usually mediated by the production of N-acyl-homoserine lactone (AHL) 
signalling molecules. A. baumannii contains the abaI gene which encodes for an AHL 
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molecule AbaI which is believed to have a role in quorum sensing (Bhargava et al., 
2010; Niu et al., 2008). 
 
2.3.2 Antimicrobial Resistance in Biofilms 
Biofilms have been shown to help bacteria survive in the environment and protect them 
from host immune systems and antimicrobial agents. Several mechanisms are 
considered to be involved in biofilm tolerance and resistance: 
1. Changes in the chemical microenvironment within the biofilm leading to sub-
populations within the biofilm. 
2. Higher mutation rate and horizontal gene transfer. 
3. Upregulation of efflux pumps. 
 
Changes in chemical microenvironment: oxygen and nutrient levels decrease from the 
surface of the biofilm to the inner layers. As a result, some bacteria within the biofilm 
exhibit stationary phase physiology with slow metabolic and growth rates. Some 
antibiotics, such as β-lactams, require metabolically active cells to exert their 
bactericidal activity (Høiby et al., 2010). However, other research has demonstrated 
that bacteria with higher metabolic activity are more resistant against colistin as 
bacteria in the inner layers of the biofilm were killed and those on the outer layers 
survived (Nuri et al., 2015; Donlan and Costerton, 2002). 
Mutation rate: the increase in mutation frequency and horizontal gene transfer within a 
biofilm involves the reduced expression of DNA repair genes and an elevation in 
oxidative stress (Nuri et al., 2015).  
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Efflux pumps have been shown to confer antimicrobial resistance in many bacteria in 
both planktonic and biofilm states and also to be upregulated when in a biofilm (Nuri et 
al., 2015). 
 
2.4 Antimicrobial Peptides 
With over 2400 catalogued, antimicrobial peptides (AMPs) represent a diverse group 
of polypeptides. They are commonly short in length (15-50 amino acids), usually 
amphipathic and have a net positive charge. AMPs are involved in the innate immune 
system of practically all living things including plants, invertebrates, fish, and mammals 
(Li et al., 2012; Lakshmaiah et al., 2015). 
 
2.4.1 Natural Function 
The primary function of AMPs involves killing pathogenic organisms such as bacteria, 
fungi, parasites and viruses. They also have a role in the induction of angiogenesis, 
wound repair, chemotaxis of immune cells to sites of inflammation, and the 
neutralization of endotoxins or septic effects of bacterial molecules such as 
lipopolysaccharide. AMPs can be present within primary barriers, preventing the 
colonisation of tissues by bacteria, fungi and viruses; they are also within phagocytes, 
as part of granules, to enhance phagocytosis (Jenssen et al., 2006; Guaní-Guerra et al., 
2010). 
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2.4.2 Antimicrobial Mechanism 
AMP characteristics consist of a net cationic charge, the ability to assume a range of 
secondary structures such as α-helices or β-sheets and being amphipathic, by 
containing both hydrophilic and hydrophobic regions (Brogden, 2005). A key difference 
in the composition of bacterial membranes compared to eukaryotic membranes is the 
presence of a net negative charge, instead of a neutral charge. This results in greater 
affinity of cationic peptides binding to bacterial cells (Laverty et al., 2011). The first 
interaction between the peptide and bacterial cell surface is thought to be electrostatic 
attraction due to the difference in charge (Brogden, 2005). When the peptides attach to 
the cell surface, they interact with the membrane’s lipid bilayers exerting their 
bactericidal effects by: 
1. Membrane disruption leading to cell lysis 
2. Formation of transient pores resulting in the transportation of peptides into the 
cell to interact with intracellular targets 
Hydrophilic positively charged domains of the AMPs interact with the negatively 
charged microbial surface and head groups of the phospholipids to cause cell 
penetration (Li et al., 2012). There are four commonly described modes of membrane 
interaction of AMPs: 
1. The Toroidal Pore Model 
2. The Carpet Model 
3. The Barrel Stave Model 
4. The Aggregate Channel Model 
 
The toroidal pore model (Figure 2.4.1) involves the peptide binding and inserting itself 
perpendicularly into the cell membrane by electrostatic interactions between the 
phospholipid head of the bilayer and the hydrophilic regions of the peptide. This leads 
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to a positive curvature of the bilayer so the peptides and lipid head groups both line the 
pore (Maria-Neto et al., 2015).  
 
 
Figure 2.4.1-Simplified image of the toroidal pore model. Pores are composed of peptides and 
phospholipid head groups causing local change of membrane thickness. 
 
In the carpet model (Figure 2.4.2), the AMPs cover the cell surface, until a threshold 
concentration is achieved; micelles are formed along with the formation of pores 
through the membrane (Laverty et al., 2011; Li et al., 2012; Nguyen et al., 2011; Maria-
Neto et al., 2015). 
 
 
Figure 2.4.2-Simplified image of the carpet model. The AMP breaks off membrane lipids into 
micelle-like structures. 
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The barrel stave model (Figure 2.4.3) is similar to the toroidal pore model whereby the 
peptides insert themselves perpendicularly into the membrane and form barrel-like 
clusters creating transmembrane pores. This can result in cell death by leakage of 
cellular contents and loss of polarisation across the membrane (Laverty et al., 2011; Li 
et al., 2012; Nguyen et al., 2011; Maria-Neto et al., 2015). 
 
Figure 2.4.3-Simplified image of the barrel stave model. Peptides form lined pores across the 
membrane. 
 
The aggregate channel model involves competitive displacement of cations Mg2+ and 
Ca2+ within the lipopolysaccharide resulting in membrane destabilisation (Li et al., 
2012). 
Along with interacting with the bacterial cell membrane, AMPs have been shown to 
interact with intracellular targets. By binding to DNA, RNA and proteins, they interfere 
with cell wall synthesis, nucleic acid synthesis, protein synthesis and enzymatic activity 
(Brogden, 2005; Li et al., 2012). 
 
2.4.3 Advantages and Disadvantages of AMPs 
Most AMP action is a result of the initial electrostatic interaction between the positive 
domains of the AMP and the negative bacterial surface. The bacteria will therefore need 
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to extensively alter the properties of their membrane, not just specific receptors often 
seen in classical antibiotic resistance, to become less susceptible to AMPs (Li et al., 
2012). 
The advantages of AMPs include: 
1. Rapid onset killing. 
2. Broad-spectrum activity. 
3. Bactericidal activity. 
4. Specific targets/receptors on the cell surface not needed for bactericidal 
activity. 
5. Potentially low levels of induced resistance. 
6. Concomitant broad anti-inflammatory activities (Gordon and Romanowski, 
2005). 
 
There have been reports of resistance against antimicrobial peptides and the resistance 
mechanisms have been found to be similar to the mechanisms against antibiotics. 
These mechanisms include alterations in the net surface charge, alterations in lipid A, 
changes in outer membrane protein production, production of proteolytic enzymes and 
role of membrane transporters (Brogden, 2005). 
Disadvantages of AMPs include: 
1. Cytotoxicity. 
2. Susceptibility to proteolytic degradation. 
3. Liable to change depending on environment such as pH. 
4. Cost of manufacturing and synthesis. 
5. Intrinsic resistance (Gordon and Romanowski, 2005). 
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Most current AMP drugs undergoing clinical trials are for topical infections due the 
cytotoxicity through systemic treatment (Lakshmaiah Narayana and Chen, 2015). The 
production costs of antimicrobial peptides is also a significant barrier if these peptides 
are to become widely used (Seo et al., 2012). 
 
2.4.4 Colistin sulphate 
Colistin sulphate, otherwise known as polymyxin E, is a member of the cationic, cyclic 
polypeptide antibiotic group known as the polymyxins and is produced by the soil 
bacterium Bacillus polymyxa (Adams et al., 2009). This group contains five members, 
polymyxin A-E, but only two, polymyxin B and E, are used in clinical treatment and 
differ only by D-phenylalanine in polymyxin B being replaced by D-leucine in 
polymyxin E (Laverty et al., 2011). 
Polymyxins are active against many Gram-negative bacteria such as A. baumannii, P. 
aeruginosa, Salmonella, Shigella, Klebsiella and Enterobacter species. They are not 
active against Gram negative or Gram positive aerobic cocci, Gram positive aerobic 
bacilli, anaerobes, fungi and parasites (Falagas and Kasiakou, 2005).  
Colistin sulphate was discovered in 1949 and used therapeutically during the 1950s 
but was believed to have significant side effects such as nephrotoxicity, mainly acute 
tubular necrosis, and neurotoxicity associated with vertigo and ataxia. As a result the 
intravenous use was restricted to treatment for lung infections caused by MDR Gram-
negative bacteria in cystic fibrosis patients (Karageorgopoulos and Falagas 2008). 
Colistin sulphate is now currently used as a last resort treatment due to the emergence 
of MDR Gram-negative bacteria such as A. baumannii which are resistant to 
carbapenems, cephalosporins and aminoglycosides and the paucity of therapeutic 
treatment alternatives (Falagas and Kasiakou, 2005; Potron et al., 2015).  
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2.4.4.1 Antimicrobial Mechanism 
In treatment, colistin sulphate can be administered orally or topically and targets the 
cell membrane of Gram-negative bacteria. Electrostatic interactions account for the first 
interactions between the cationic polypeptide of colistin and the anionic endotoxic 
component of the lipopolysaccharide (LPS), lipid A (Moffatt et al., 2010; Falagas and 
Kasiakou, 2005). Colistin uses the aggregate channel model as described in Section 
2.4.2 whereby it displaces the cations Mg2+ and Ca2+ which normally stabilise the LPS 
layer. This results in permeability changes in the membrane, leading to cell content 
leakage and ultimately cell death (Falagas and Kasiakou, 2005). 
Colistin sulphate has a molecular weight of 1155.4 g/mol and its structure includes two 
distinct hydrophobic regions, the N-terminal fatty acyl chain and the Phe-Leu segment 
as shown in orange in Figure 2.4.4. The hydrophilic cycloheptapeptide ring includes 
three positively charged amine residues, shown in green. The colistin peptide is folded 
such that the hydrophobic and hydrophilic components form two distinct faces 
resulting in structural amphipathicity.  This allows the interaction with constituents of 
the lipopolysaccharide such as lipid A where the hydrophobic regions interacts with the 
lipid A fatty acyl chains while the hydrophilic residues face in the opposite way towards 
the aqueous environment. (Velkov et al., 2010; Rhouma et al., 2015). 
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Figure 2.4.4-Structure of Colistin sulphate. Molecular formula of C52H98N16O13 (Chembase, 2014). 
Orange annotations indicates hydrophobic residues, blue indicates hydrophilic regions and 
green indicates polar groups (Velkov et al., 2010). 
 
2.4.4.2 Resistance 
A. baumannii resistance to colistin sulphate is believed to be the result of two main 
mechanisms: 
1. The first involves mutations in the genes, lpxA, lpxC or lpxD, that affect the 
encoding enzymes responsible for lipid A biosynthesis. These mutations lead to 
subsequent inability to produce lipid A and LPS (Moffatt et al., 2010; Potron et 
al., 2015; Durante-Mangoni et al., 2015). 
2. The second mechanism involves mutations in the genes, pmrA and pmrB, that 
encode the PmrAB two-component system which is involved in environmental 
sensing of Fe3+, Mg2+ and pH. Changes in this system can lead to altered gene 
expression resulting in lipid A modification (Adams et al., 2009). 
 
Modifications to lipid A can lead to the reduction or elimination of the initial charged 
electrostatic interaction between the colistin sulphate and lipid A. This can also reduce 
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the negative charge of the LPS and therefore lowering its affinity to colistin (Moffatt et 
al., 2010).  
The result of reduced levels, or complete loss of LPS, decreases the anionic charge of 
the outer membrane of the bacterial cell and therefore decreases the affinity of the 
cationic charged polypeptide of colistin. Hetero-resistance of A. baumannii against 
colistin could be due to the presence of cells that have random mutations in these key 
genes (Moffatt et al., 2010). 
 
2.4.4.3 Relation to this Project 
Colistin sulphate is a currently used as antimicrobial treatment of last resort against A. 
baumannii infections. In this project its effectiveness was compared with the AMPs 
bicarinalin and BP100 against both planktonic cells and biofilms of A. baumannii. 
 
2.4.5 Bicarinalin 
Bicarinalin is an amphipathic, C-terminally amidated, novel antimicrobial peptide 
derived from the venom of the myrmicine ant, Tetramorium bicarinatum (Rifflet,et al., 
2012).  
It consists of a sequence of 20 amino acid residues (KIKIPWGKVKDFLVGGMKAV) with a 
molecular weight of 2213.78 g/mol. Ant venom is an area of research interest that has, 
to date, been poorly studied compared to other animal venoms although other AMPs 
have been identified in other ant genera such as the ponericins from Pachycondyla 
goeldii and pilosulin from Myrmecia pilosula (Rifflet et al., 2012). 
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Figure 2.4.5-Vial containing bicarinalin as white lyophilised conforms. Created by GenScript. 
97.7% purity and structure was confirmed by high performance liquid chromatography (HPLC) 
 
Rifflet (2012) evaluated the antibacterial activity of bicarinalin using a synthetic 
replicate against Staphylococcus aureus and Staphylococcus xylosus in comparison to 
melittin, another AMP, and standard antibiotics ampicillin and tetracycline. They found 
bicarinalin had similar antibacterial activity against S. aureus but was more potent than 
melittin and tetracycline against S. xylosus. 
Bicarinalin also has the advantage of weak haemolytic activity compared to melittin 
against erythrocytes which has been a significant obstacle for using AMPs in treatment 
against antibiotic-resistant pathogens. It also highlighted that bicarinalin had similar 
antibacterial activity as other AMPs such as defensin, pilosulin and scolopin but was 
generally less haemolytic. (Rifflet et al., 2012). 
Tene (2014) further tested the bacteriostatic and bactericidal effects of bicarinalin 
against Cronobacter sakazakii and four species of Enterobacter: E. cloacae, E. 
aerogenes, E. hormaechei and E. cloacae while comparing the results with melittin, 
ampicillin and tetracycline. Bicarinalin was found to be more potent than melittin and 
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the other antibiotics against all of the bacteria tested by Tene (2014.) Bicarinalin is 
considered to be a promising candidate for treatment against resistant bacterial strains 
and other potential applications such as dried food and cosmetics (Téné et al., 2014; 
Rifflet et al., 2012). 
 
2.4.5.1 Antimicrobial Mechanism 
It is believed that bicarinalin’s antibacterial mechanism is similar to other AMPs, with 
its cationic charge, as a result of lysine residues, naturally attracted to the anionic 
charged bacterial cell surface. This interaction leads to the local disruption of the 
bacterial surface (Rifflet et al., 2012). 
In Figure 2.4.6 the helix wheel for bicarinalin is shown and elucidates bicarinalin’s 
amphipathicity which is a characteristic of antimicrobial peptides. All the hydrophobic 
residues apart from Ile and Val are on one side of the helix while the hydrophilic amino 
acid residues are located on the opposite side. (Rifflet et al., 2012). 
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Figure 2.4.6-Helix wheel of Bicarinalin. Hydrophobic residues shown as green and yellow circles, 
positively charged as blue circles, hydrophilic residues as grey and red circles,  (Rifflet et al., 
2012). 
 
2.4.5.2 Relation to this project 
Bicarinalin was chosen for this project because it has been shown to have higher 
antimicrobial potency compared to currently used antibiotics; it is not cytotoxic at 
bactericidal doses and has proven activity against Gram-negative bacteria. There is also 
no evidence in the literature of it ever being tested against A. baumannii (Téné et al., 
2014; Rifflet et al., 2012). 
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2.4.6 BP100 
BP100 is a short C-amidated undecapeptide peptide consisting of eleven amino acid 
units (KKLFKKILKYL) and a molecular weight of 1420.88 g/mol. It was originally made 
through combinatorial chemistry involving two peptides, cecropin A and melittin 
(Alves et al., 2010). 
Cecropin A is a member of the well-researched AMP family, the cecropins, first isolated 
from the giant silk moth Hyalophora cecropia. The cecropin family, although 
susceptible to protease degradation, do not exhibit cytotoxic effects against human 
erythrocytes (Badosa et al., 2007; Ferre et al., 2009). 
Melittin is a 26 amino acid, haemolytic alpha helical peptide first purified from the 
European honeybee in 1958 (Hou et al., 2015). Melittin has been shown to have high 
antibacterial activity. However, on its own, its strong cytotoxic action, makes it 
unsuitable for applications in antibiotic treatment (Pott et al., 2015). 
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Figure 2.4.7 Vial containing BP100 as white lyophilised conforms. Created by GenScript. 98.4% 
purity and structure was confirmed by high performance liquid chromatography (HPLC) 
 
To circumvent cercropin A’s susceptibility to proteolytic degradation and melittin’s high 
cytotoxicity, they were combined to produce a derivative, BP100. BP100 exhibits low 
susceptibility to protease degradation and low cytotoxicity against erythrocytes and 
fibroblasts (Manzini et al., 2014). BP100’s bactericidal activity has been established to 
be highly active, discerning Gram-negative bacteria including plant pathogens such as 
Erwinia amylovora, Pseudomonas syringae and Xanthomonas azonopodis (Ferre et al., 
2009) and the human pathogen Escherichia coli (Alves et al., 2010). 
 
2.4.6.1 Antimicrobial Mechanism 
It is believed that BP100 interacts with the bacterial cell membrane by its electrostatic 
attraction to the negatively charged LPS layer. (Alves et al., 2010). 
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The helix wheel as shown in Figure 2.4.8 indicates the presence of positively charged 
Lys residues on one side of the peptide (pentagons) and on the opposite side there are 
hydrophobic residues (diamonds). BP100, consisting of only 11 amino acids, is not long 
enough in length to transverse the span of the phospholipid bilayer to form 
transmembrane pores. The carpet model model is therefore considered as the most 
likely mechanism of action as shown in Figure 2.4.2. (rzlab, 2016; Wadhwani et al., 
2014 ). 
 
Figure 2.4.8-Helix wheel of BP100. Hydrophobic: diamond high (green) low (yellow), Positive 
charge: pentagons (rzlab, 2016). 
 
2.4.6.2 Relation to this Project 
BP100 was chosen because of its high bactericidal activity against Gram-negative plant 
pathogenic bacteria and Escherichia coli and its low cytotoxic activity (Alves et al., 
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2010; Güell et al., 2012; Badosa et al., 2007). There is also no evidence in the literature 
of it ever being tested against A. baumannii. 
2.5 Visualisation Techniques 
This project used three microscopes, the atomic force microscope (AFM), scanning 
electron microscope (SEM) and the confocal laser scanning microscope (CLSM) to 
investigate the effect of the three antimicrobial peptides: colistin sulphate, bicarinalin 
and BP100 on Acinetobacter baumannii planktonic cells and biofilms. 
 
2.5.1 Atomic Force Microscopy 
The AFM was first invented in 1986 and since has become widely used in biomedical 
research such as virology, microbiology, biomaterials, nanotechnology and genetics. 
(Chang et al., 2012) Its ability to map surfaces at micrometre to nanometre resolution 
and used in tandem with conventional microscopes has allowed in-depth analysis and 
detailed imaging at a molecular level (Chang, et al., 2012; Longo and Kasas, 2014). 
The bacteriostatic and bactericidal concentrations of the peptides on planktonic A. 
baumannii cells were determined through microbiological assays. In this project the 
consequence of this activity was then visualised using the AFM. 
 
2.5.1.1 Fundamentals of AFM Operation 
The AFM consists of four parts:  
 a probe that consists of a cantilever with a sharp tip mounted on the end, made 
of silicon or silicon nitride (Figure 2.5.1) 
 a piezo scanner that drives the cantilever  
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 a laser diode  
 a detector 
 
Figure 2.5.1- SEM Images of the cantilever and tip. Image A shows AFM cantilever and tip while 
image B shows close up of silicon tip. (Bruker, 2015). 
 
There are two main modes of AFM: contact mode and non-contact mode. In contact 
mode, the tip of the probe is brought into contact with the sample or bacterial surface 
and is dragged or scanned over the required surface area in a raster pattern. Surface 
features cause the displacement of the cantilever which is measured by the detector 
through the deflection of the laser beam reflected from the back of the cantilever. The 
laser deflection is plotted and a topographic image of the sample surface is produced 
(Chang et al., 2012) (Figure 2.5.2). 
Non-contact mode allows the measurement of attractive forces such as van der Waals 
or dipole interactions between the tip and the bacterial surface. This involves 
oscillating the cantilever above the surface of the bacterial surface and measuring the 
alterations in amplitude or frequency of the cantilever (Chang et al., 2012). 
Contact mode has the inherent problem that lateral forces applied on the sample 
surface can cause damage and move loosely attached objects (Kaemmer, 2011). To 
circumvent this problem, a newer type of contact mode, “PeakForce Tapping” was 
A B 
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made. This requires the cantilever to oscillate, resulting in the tip touching the surface 
for a short amount of time and then being lifted up again. This mode has a drawback in 
that the interaction force between the tip and the sample surface is fixed during 
scanning which may lead to damage to the sample along with false imaging (Kaemmer, 
2011).  
 
 
Figure 2.5.2-Simplified image of AFM setup. A laser beam is directed onto the back of the probe 
while the probe is moving up and down on the sample. The beam is then reflected into the 
detector and an image of the surface topography is produced (Bruker, 2011).  
 
In this project the “PeakForce Tapping” mode was used with “ScanAsyst” software. The 
programme includes an algorithm that automatically adjusts all critical parameters 
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such as gain, scan-rate and z-limit in real-time to optimize imaging. This is especially 
important for samples that have both soft and hard areas such as bacterial cells fixed on 
glass slides (Kaemmer, 2011) as used in this project. 
 
2.5.1.2 Advantages and Limitations 
The AFM has numerous advantages over conventional electron and optical 
microscopes. The first is the simplicity of sample preparation. It also does not require 
the use of fluorescent dyes as in the CLSM (Section 2.5.3) or vacuuming or metal 
coating as required in the scanning electron microscope (Section 2.5.2). The bacterial 
cell samples can be grown on, or suspensions can be pipetted onto, flat surfaces such as 
graphite, silicon, glass slides or modified surfaces such as poly-lysine coated surfaces. 
This ensures, during preparation, there is little disruption to the samples. The samples 
can also be visualised in liquid as well as in air permitting the analysis of samples 
within their physiological buffer solutions. The resolution of AFM scanning enables the 
visualisation of samples at nanometre or micrometre scales (Chang et al., 2012). 
The AFM has become a valuable and widespread tool in imaging studies but as with all 
equipment there are limitations. The primary limitation is that the AFM is only able to 
obtain surface information from samples so other microscopes, such as transmission 
electron microscopes, optical microscopes and fluorescence microscopes, are also used 
in conjunction (Chang et al., 2012). 
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2.5.2 Scanning Electron Microscopy 
The SEM was used to visualise the effects of a range of peptide concentrations on 
biofilms. The concentrations were determined at which the peptides removed the 
majority of the biofilm grown by A. baumannii; the effects of this activity was then 
visualised using the scanning electron microscope. 
2.5.2.1 Fundamentals of SEM Operation 
From the electron gun, located at the top of the SEM, accelerated electrons are fired at a 
sample (Figure 2.5.3). These electrons pass through electromagnetic lenses forming a 
focused spot, potentially 2 nm in diameter, of electrons that is scanned over a sample 
(Zhou et al., 2007; Güell et al., 2012; Kaláb et al., 2008). 
Secondary electrons are formed when a primary electron dislodges an electron from 
the sample surface. Secondary electrons have low energy levels which mean they can 
only be detected when they are dislodged near the surface of the sample. These 
electrons are reflected into the secondary electron detector where is signal is produced. 
(Zhou et al., 2007). 
The signals are processed and translated into pixels creating a 2D impression of the 
sample surface morphology. The SEM is under a vacuum, usually below 10-6 Torr, to 
remove any air molecules that would impede the electron beam as well as the 
secondary electrons travelling to the detector (Zhou et al.,2007; Alhede et al., 2012). 
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Figure 2.5.3-Simplified image of SEM setup. Accelerated electrons are fired at a sample and pass 
through an anode and magnets which creates a narrow focused spot of electrons. Secondary 
electrons are released from the sample and are detected by a detector which creates an image of 
the sample surface (Alhede et al., 2012). 
 
Most bacterial sample preparation for SEM work includes the use of a buffer such as 
sodium cacodylate and a fixative such as glutaraldehyde. The buffer is used to produce 
an isotonic solution for the sample and to protect the sample from becoming acidic. The 
glutaraldehyde is used to preserve the structure of the sample tissues when within a 
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vacuum. The specimen is dehydrated with increasing concentrations of methanol to 
remove any water. The sample is then mounted and coated in a thin layer of conductive 
metal such as gold, carbon or platinum which is usually applied via the sputter coating 
method (Kaláb et al., 2008; Alhede et al., 2012). 
 
2.5.2.2 Advantages and Limitations 
The SEM is able to produce high resolution, high magnification images of the sample 
surface. It is relatively easy to operate and sample preparation is straightforward 
although time consuming. The primary limitations of the SEM are that only the surface 
topography of the sample can be analysed and limited quantitative data can be 
obtained during or after the imaging. The preparation of the sample, in the case of 
bacteria, involves dehydration, and can cause alterations in morphology and structure 
and only dead samples can be visualised (Alhede et al., 2012). 
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2.5.3 Confocal Laser Scanning Microscopy 
The concept of the confocal laser scanning microscope (CLSM) was developed in the 
1950s with the first commercial instrument appearing in 1987. However, it was not 
until the late 1990’s when the CLSM began to be widely used (Claxton et al., 2006; 
Lavrentovich, 2012) . 
In this project the CLSM was used to analyse the biofilm produced by A. baumannii by 
creating 3 dimensional images by a process of Z stacking. The samples were visualised 
by staining with the nucleic acid fluorochrome, SYTO9. The biofilm was quantified by 
calculating the bio-volume of the biofilm after it had been subjected to increasing 
concentrations of each of the three peptides, colistin sulphate, bicarinalin and BP100. 
 
2.5.3.1 Fundamentals of CLSM Operation 
The confocal microscope uses a laser for the light source and acousto-optic tuneable 
filters (ATOFs) to select specific excitation wavelengths. The laser passes through a 
dichroic mirror which selectively transmits light of a chosen wavelength (Figure 2.5.4). 
This light is reflected into the back focal plane of the objective lens which in turn 
focuses the laser light at a specific point on a sample which is stained with the 
fluorochrome (Claxton et al., 2006). 
When a photon from the laser beam is absorbed by a fluorophore, an electron within 
the sample is excited by entering a higher, unstable energy state. The electron is in this 
higher energy state for a few nanoseconds then falls back to the original ground state. 
As it falls, light is emitted as a characteristic wavelength (Claxton et al., 2006; 
Lavrentovich, 2012). 
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Figure 2.5.4-Simplified image of CLSM setup. A laser beam of a certain wavelength reaches the 
sample and excites the fluorophore. Light of a certain wavelength is emitted and reflected by a 
dichroic mirror through a pinhole only allowing focused light through to the photomultiplier 
(Claxton et al., 2006). 
 
The light, emitted from the excited fluorochrome, passes back through the objective 
lens. As this light is of a longer wavelength in relation to the excitation light, it does not 
go through the dichroic mirror, but is instead reflected through another pinhole. This 
pinhole is specifically located to only allow in-focused light through while blocking any 
out-of-focus light. Beyond the pinhole, there are filters that allow further 
discrimination of wavelength to pass through to a photomultiplier tube or PMT. The 
PMT is calibrated to detect the required wavelengths. Within a photomultiplier tube, an 
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incoming photon hits an electron within the photocathode which initiates a chain 
reaction of electrons and hence detection on the screen (Claxton et al., 2006). 
The fluorescent stain used in this project was SYTO9; a nucleic acid membrane 
permeable stain and stains all cells whether the bacteria membranes are intact or not 
(Stocks, 2004). The excitation and emission wavelengths of SYTO9 are shown in Figure 
2.5.5.  
 
 
Figure 2.5.5- SYTO9 excitation wavelength in blue and emission wavelength in red. Peak 
excitation 485nm and peak emission 498nm (ThermoFisher Scientific, 2015). 
 
2.5.3.2 Advantages and Limitations 
The main advantage of the CLSM is the ability to collect serial optical sections of a 
sample; made possible by the pin-hole eliminating out-of-focus light before it reaches 
the photomultiplier and the ability to coordinate the imaging along the Z axis. 
Compiling these sections into a Z stack, creates a 3D image which can be analysed and 
quantitative data can be obtained. This is a non-invasive technique allowing the 
analysis of thick samples without the need to break up the sample. The samples can 
also be analysed in normal laboratory conditions in contrast to the SEM that requires a 
vacuum and detailed sample preparation (Claxton et al., 2006). 
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There are a few limitations of the CLSM. One is the limited number of excitation 
wavelengths available with the commonly used lasers. Intensive laser irradiation may 
be harmful to living cells and tissues and the high costs associated with the purchasing 
and operating of a CLSM (Claxton et al., 2006). 
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3 Materials and Methods 
3.1 Materials 
The following section lists all the materials used in the research project including the 
manufacturing company: 
Product Supplier Additional Information 
¼ strength Ringer’s 
Solution 
Oxoid 1 tablet per 500ml of distilled 
water 
25 % Glutaraldehyde 
Solution 
Fisher Scientific  
Absolute Ethanol Fisher Scientific  
Acinetobacter baumannii 
ATCC 19606 
Thermo Scientific  
API 20NE BioMérieux Clinical 
Diagnostics 
API 20NE reagents kit. 
James, NIT 1, NIT 2, Zinc 
Powder 
Bicarinalin Genscript Amino acid sequence: 
KIKIPWGKVKDFLVGGMKAV 
Molecular weight: 2213.78 
C-terminally amidated 
BP100 Genscript Amino acid sequence: 
KKLFKKILKYL 
Molecular weight: 1420.88 
C-terminally amidated 
Chlorine Release Tablets 
(Haz-tabs) 
Appleton Woods  1 tablet per 250ml of water 
Colistin Sulphate Sigma-Aldrich  
Crystal Violet ProLab  
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Gram’s Iodine ProLab  
Baclight Live/dead stain ThermoFisher Scientific Contains 3.34mM SYTO9 
Methanol Fisher Scientific  
Mineral Oil Sigma-Aldrich  
N,N,N',N'-Tetramethyl-p-
phenylenediamine 
dihydrochloride,>=95 
%, powder 
Sigma-Aldrich  
Safranin ProLab  
Sigma-Aldrich Sodium 
cacodylate trihydrate. 
  
Tryptone Soya Agar 
(TSA) 
Oxoid An equivalent of 40g of 
Tryptone soya agar powder 
was weighed and dissolved in 
1 litre of distilled water 
Tryptone Soya Broth 
(TSB) 
Oxoid An equivalent of 30g of 
Tryptone soya broth powder 
was weighed and dissolved in 
1 litre of distilled water 
Virkon S disinfectant Virkon  
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3.2 Equipment 
The equipment used in the project, including the manufacturing company, is listed 
below: 
Product Supplier Additional Information 
0.5” aluminium 
specimen stubs. 
Agar Scientific  
1000 µl, 200 µl, 10 µl 
pipettes 
Bioscope or Sarstedt  
1000 µl, 200 µl, 10 µl 
tips 
Bioscope/Sarstedt  
1ml syringe Plastipak Sterile 
10ml pipettes Sarsted Serological, non-cytotoxic, non 
pyrogenic 
25ml pipette Fisher Brand Disposable serological pipettes 
211DS Shaking 
Incubator 
Labnet  
96 Well Plates Sarstedt Sterile 
Atomic Force 
Microscope Tips-
SCANAYST AIR, Silicon 
top on nitride Lever 
Bruker Cantilever- Tip height-650nm 
Cantilever length-115µm 
Cantilever width-25µm 
Resonance frequency (F0)-70kHz 
Spring constant (k)-0.4N/m 
Bioscope Catalyst 
Atomic Force 
Microscope with Easy 
align and Scanayst 
Bruker  
Nunc-TSP Screening 
Plate Lids 
ThermoScientific  
Chambered #1.0 
Borosilicate 
Labtek  
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Coverglass System-8 
chamber 
Colourimeter Fisher Scientific  
Confocal Laser 
Scanning Microscope 
Leica TCS SP8  
Cuvettes Sarstedt 1ml polystyrene 
Filter Sartorius Stedium 
biotech 
0.2µm minisart single use filter-
sterile, non-pyrogenic 
Incubator Thermo Scientific 37°C 
Electronic Pipette Scientific Laboratory 
Supplies (SLS) LTD 
Integra Pipetboy 2 
Light Microscope. Zeiss Primo Star  
L-shaped Spreaders. Scientific Laboratory 
Supplies (SLS) LTD 
Sterile 
Micro tubes. Sarstedt  
Mili-Q water 
dispenser. 
Purelab flex 18.2Ω 
NanoDrop 2000c 
Spectrophotometer. 
Thermo Scientific  
Inverted Microscope Nikon Eclipse TE2000-
S. 
 
Parafilm “M” 
laboratory film. 
Parafilm  
Poly-L-lysine coated 
slides. 
Sigma Aldrich  
Scanning Electron 
Microscope 
FEI Quanta FEG 650  
Sterile disposable 
serological 10ml 
Pipettes. 
Fisherbrand  
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3.3 Software Programs 
The following programs were used to analyse the results: 
 NanoScope Analysis Version 1.50 (Bruker, 2015) 
o Used to create and obtain images of cells from the AFM. 
 
 Gwyddion (Necas and Klaptek, 2012) 
o Used in the analysis and quantification of surface roughness and surface 
area of cells imaged by AFM. 
 
 Las X (Leica Microsystems, 2015) 
o Used to acquire and analyse CLSM images. 
 
 BITPLANE Imaris x64 Version 8.1.2 (Bitplane, 2015) 
o Used in the quantification of bio-volume of biofilm of CLSM images. 
 
 IBM SPSS Statistics 21 (IBM Corp, 2012) 
o Used in the statistical analysis of results. 
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3.4 Reoccurring Calculations 
3.4.1 Absorbance Calculation 
The absorbance calculation was used throughout the project to obtain a standard initial 
inoculum containing approximately 5x105 viable cells per ml (2-7x105 CFU/ml) at the 
start of each experiment. The British Society for Antimicrobial Chemotherapy (BSAC) 
recommends this concentration as a standard for susceptibility testing of bacteria 
(Andrews, 2006). 
Tryptone soya broth (TSB) was prepared as described in Section 3.1. 10ml of TSB was 
pipetted into glass universals and autoclaved for 15 minutes at 121°C. A glass universal 
(labelled #1), containing 10 ml sterile TSB, was inoculated with 2-3 colonies of A. 
baumannii 19606 taken from a Tryptone soya agar (TSA) plate, grown for 24 hours at 
37°C. The broth was then incubated overnight at 37°C. 
The following day, the absorbance of this overnight broth was measured by pipetting 1 
ml into a 1 ml polystyrene cuvette and using a colorimeter (set at a wavelength of 590 
nm) calibrated against a 1 ml blank containing sterile TSB.  
Applying Equation 1 below, a calculated volume of overnight broth was pipetted into 
another universal (labelled #2) containing 9 ml sterile TSB, to give a final volume of 10 
ml and a final desired absorbance reading of 0.01. This was confirmed by pipetting 1 ml 
of this solution into a cuvette and measuring against a sterile TSB blank. The 
absorbance of 0.01 was chosen as it equated to a cell density of approximately 1x107 
CFU/ml based on the results of the growth curve as described in Section 4.2.  
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟏:          𝑽𝟏 =
𝑨𝟐  𝑽𝟐
𝑨𝟏
 
Where: 
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V1=The unknown volume of overnight culture to be added 
A1=Initial absorbance reading of the overnight culture at 590 nm 
A2=Desired absorbance reading (0.01). 
V2=Final volume of TSB within universal (10 ml). 
For example: 
An overnight broth culture containing Acinetobacter baumannii 19606 was removed 
and an absorbance reading of 0.9 was measured against a 1 ml blank which contained 
sterile TSB taken from the universal that is going to be inoculated. If an absorbance 
value of 0.01 is desired, the volume of culture to be added (V1) is: 
𝑽𝟏 =
𝟎. 𝟎𝟏 𝒙 𝟏𝟎 𝒎𝒍
𝟎. 𝟗
 
𝑽𝟏 = 𝟎. 𝟏𝟏 𝒎𝒍 
After mixing on a vortex at 500rpm for 10 seconds, 0.11 ml was transferred from the 
overnight broth to the glass universal currently holding 9 ml (as 1 ml was already used 
for the blank). From a third universal containing sterile TSB, 0.89 ml is removed and 
added to the newly inoculated TSB to make a final volume 10ml with a cell density of 
approximately 1x107 CFU/ml. After vortexing, 1 ml is removed and its absorbance is 
measured to confirm it is 0.01. 1 ml of this solution was then pipetted into 9ml of sterile 
TSB broth to give a theoretical cell density of approximately 1x106 CFU/ml. 
A final two-fold dilution would then be made to obtain the required concentration of 
approximately 5x105 CFU/ml (range of 2-7x105 CFU/ml) (as recommended by BSAC) 
(Andrews, 2006) which was the concentration used for all experiments. This was 
confirmed during each experiment by the plate spread method. 
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3.4.2 Concentration Calculation 
The concentration calculation was used to ensure a final desired concentration of a 
substance, for example, a peptide was present in a certain volume of solution. A 
standard stock concentration 1024 µg/ml of antimicrobial peptide was prepared for 
determination of the minimum inhibitory concentration (MIC), minimum bactericidal 
concentration (MBC) and minimum biofilm inhibitory concentration (MBIC) as 
discussed in Sections 3.10, 3.11 and 3.12. The stock solution was made by firstly 
weighing 5000µg of peptide within a microtube and dissolving it in 1ml of distilled 
water to give a peptide concentration of 5000 µg/ml. A stock solution of peptide, for 
example colistin sulphate, at a concentration of 1024 µl was produced using Equation 2 
below. 
  𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐:          𝑽𝟏 =
 𝑪𝟐 𝑽𝟐
𝑪𝟏
 
 
C1= Concentration of dissolved antimicrobial peptide (5000 µg/ml) 
V1= Unknown volume of antimicrobial peptide to be added (ml) 
C2= Required concentration of antimicrobial stock (1024 µg/ml) 
V2=Final volume of stock (1ml) 
 
Using the equation above, V1 was calculated as: 
𝑽𝟏 =
𝟏𝟎𝟐𝟒 𝒙 𝟏
𝟓𝟎𝟎𝟎
 
𝑽𝟏 = 𝟎. 𝟐𝟎𝟒𝟖𝒎𝒍 
0.2048ml of 5000 µg/ml was pipetted into 0.7952ml milli-Q water to make a final 
concentration of 1024 µg/ml. For bicarinalin and BP100, the purity was also 
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considered. For example, as bicarinalin had a purity of 97.7 % (Section 2.4.5), 5000µg 
of bicarinalin was weighed and dissolved in 1ml distilled water and using the following 
equation the true amount was calculated.  
𝑻𝒓𝒖𝒆 𝒎𝒂𝒔𝒔 (µ𝒈) = (
𝟗𝟕. 𝟕
𝟏𝟎𝟎
) ∗ 𝟓𝟎𝟎𝟎 
𝑻𝒓𝒖𝒆 𝒎𝒂𝒔𝒔 (µ𝒈) = 𝟒𝟖𝟖𝟓µ𝒈 
Equation 2 was then used to obtain a stock solution of 1024 µg/ml of bicarinalin.  
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3.5 Colony Morphology Analysis 
3.5.1 Objective 
The culturing of bacteria on solid media, such as TSA, allows the bacteria to form 
visible colonies which can be used to help identify certain bacteria based on distinctive 
characteristics such as the shape, size (diameter in millimetres), edge/margin, colour, 
opacity, surface consistency and elevation. 
 
3.5.2 Methodology 
A culti-loop of Acinetobacter baumannii 19606 was streaked, in aseptic conditions, on a 
freshly prepared TSA plate. This was incubated for 24 hours at 37°C. After 24 hours, a 
single colony of A. baumannii 19606 was removed with a wire loop under aseptic 
conditions and streaked onto another TSA plate and incubated for a further 24 hours at 
37°C. The colony morphology was analysed by measuring and recording the physical 
attributes observed (Section 4.1). 
 
3.6 Gram Staining and Light Microscope Analysis 
3.6.1 Objective 
The Gram stain is a technique first developed in 1884 by the Danish scientist Hans 
Christian Gram and is used to differentiate between two basic groups of bacteria, Gram-
positive and Gram-negative. The technique uses three stains and ethanol:  
 Crystal Violet, the primary stain, 
 Iodine, the mordant,  
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 Ethanol, the decolourising agent, 
 Safranin, the counterstain.  
Gram-positive cells stain dark purple from the crystal violet and Gram-negative cells 
stain pink/red from the safranin (Bauman, 2012).  
 
3.6.2 Methodology 
The following procedure, recommended by the University of Lincoln Microbiology 
Laboratory, was adopted for Gram staining A. baumannii. A drop of distilled water was 
pipetted onto a clean glass slide. A colony of A. baumannii was removed with a wire 
loop from the surface of a streaked TSA plate which had been grown at 37°C for 24 
hours. The colony was mixed with the distilled water and spread across the slide. The 
slide was left to air dry. Once dry, the slide was flooded with crystal violet for 60 
seconds. The slide was rinsed with tap water for approximately 5 seconds. 
The slide was then flooded with Gram’s iodine for 60 seconds and further rinsed with 
tap water for approximately 5 seconds. The slide was rinsed with 100 % absolute 
ethanol for approximately 5 seconds and then rinsed with tap water. 
The slide was then stained with safranin for 60 seconds. The slide was rinsed with tap 
water and blotted on absorbent paper. The colour and shape of the bacterial cells were 
observed under a Zeiss Primo Star Light Microscope with 10x, 20x, 40x and 63x 
magnifications and the width and length of single cells of A. baumannii were measured 
(Section 4.1).  
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3.7 Analytical Profile Index 20NE Identification Kit 
3.7.1 Objective 
The bioMérieux Clinical Diagnostics API 20NE identification kit is used to facilitate the 
identification of non-fastidious, non-Enterobacteriaceae Gram-negative rods. The kit 
was used to confirm the culti-loops contained A. baumannii. The kit consists of twenty 
cupules each containing different dehydrated substrates.  
 Eight of the cupules determine if A. baumannii is able to ferment a specific 
substrate; a colour change within the cupule indicates a positive or negative 
result.  
 Twelve cupules are assimilation tests; they are inoculated with minimal 
inoculated medium and tests if A. baumannii is able to grow by utilising the 
specific substrate. A clear cupule indicates no growth, a negative result, an 
opaque cupule indicates growth, a positive result. 
The oxidase test (Section 3.8) is not included in the API kit but was also used to confirm 
the identity of A. baumannii. 
 
3.7.2 Methodology 
Under aseptic conditions, a loop containing A. baumannii 19606 was streaked onto a 
TSA plate and incubated for 24 hours at 37°C. Using a sterile loop, one colony was 
transferred from the plate into 2ml of saline solution.  
5ml of distilled water was distributed throughout the incubation tray to create a humid 
atmosphere when incubated. Under aseptic conditions, the API strip was removed and 
placed into the incubation box. 
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The eight substrate tests were: 
 Potassium nitrate (N03) 
 Tryptophane (TRP) 
 Glucose (GLU)  
 Arginine (ADH)  
 Urea (URE) 
 Esculin (ESC) 
 Gelatine (GEL)  
 P-nitrophenyl-β-D-galactopyranoside (PNPG) 
 
The cupules were filled with the inoculated saline until the tubes were full while 
avoiding the production of air bubbles. Mineral oil was added to the GLU, ADH, URE 
tubes until a convex meniscus filled the cupules, creating anaerobic conditions. 
200 µl of the inoculated saline solution was then transferred into an ampule containing 
7ml of API AUX medium and the solution. 
The twelve assimilation tests were:  
 Glucose (GLU) 
 Arabinose (ARA) 
 Mannose (MNE) 
 Mannitol (MAN) 
 N-acetyl-glucosamine (NAG) 
 Maltose (MAL) 
 Gluconate (GNT) 
 Caprate (CAP) 
 Adipate (ADI) 
 Malate (MLT) 
58 
 Citrate (CIT) 
 Phenyl-acetate (PAC) 
 
The cupules were filled with the inoculated AUX medium while avoiding the production 
of air bubbles. The lid was placed onto the strip and incubated at 37°C for 24 hours.  
 GLU, ADH, URE, ESC, GEL, PNPG cupules: the spontaneous reactions were 
recorded as positive or negative using the colour results sheet supplied by 
bioMérieux.  
 NO3 cupule: one drop of reagents NIT1 and NIT2 were added to the cupule and 
after five minutes the result was recorded. As no colour change occurred, 2-3mg 
of zinc powder was added and left for five minutes and the resulting colour 
change was recorded. The liquid within the cupule was pipetted out and 
discarded and the cupule was filled with mineral oil until a convex meniscus 
was formed. 
 TRP cupule: a drop of JAMES reagent was added and the resulting colour change 
was recorded. The liquid within the cupule was pipetted out and discarded and 
the cupule was filled with mineral oil until a convex meniscus was formed. 
 Assimilation tests: growth was recorded as negative if the cupule was clear and 
positive if the cupule was opaque. 
 
5ml of distilled water was replenished in the incubation tray and the strip was re-
incubated for a further 24 hours at 37°C. The colours/turbidity of all the cupules were 
then recorded again except for the first three tests, NO3, TRP and GLU. A 
complementary test of growing a streak plate of A. baumannii 19606 at 44°C for 24 
hours was also carried out. 
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3.8 Oxidase Test 
3.8.1 Objective 
The oxidase test is used to test for the presence of cytochrome C oxidase, an enzyme 
involved in the bacterial electron transport chain. This test distinguishes between the 
bacterial genera such as Pseudomonas and Neisseria which are characterised as 
oxidase positive compared to oxidase negative organisms such as the 
Enterobacteriaceae family (Bauman, 2011).   
A. baumannii is not a member of the Enterobacteriaceae family but does not contain 
cytochrome c oxidases. The reagent Tetramethyl-p-phenylenediamine dihydrochloride 
(TMPD) functions as an artificial electron donor and when oxidised by oxidase, a dark 
blue/purple colour appears. If there is no colour change, the result is recorded as 
oxidase negative (Bauman, 2011; Jurtshuk and McQuitty, 1976). 
The result of this test was used as an additional part of the API identification kit and the 
results are described in Section 4.1. 
 
3.8.2 Methodology 
1g of N,N,N,N-tetramethyl-p-phenylenediamine dihydrochloride (TMPD) was dissolved 
in 100ml of distilled water. 1ml of this solution was impregnated onto filter paper. 
Using a sterile plastic loop, a sample of A. baumannii, grown on TSA for 24 hours at 
37°C, was spread across the impregnated filter paper. If a dark purple/blue colour 
appeared within 10 seconds the result was recorded as oxidase positive and if there 
was no colour change the result was recorded as oxidase negative. Pseudomonas 
aeruginosa was used as a positive control while Klebsiella pneumoniae was used as a 
negative control. 
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3.9 30 Hour Growth Curve of A. baumannii 19606 
3.9.1 Objective 
A growth curve for A. baumannii 19606 was created to investigate the following:  
1. To determine the cell density within a solution of Tryptone soya broth (TSB) at 
an absorbance of 590nm. The absorbance calculation had to be repeated at the 
start of each experiment to ensure a standard cell density of 5x105 CFU/ml 
(Section 3.4.1). 
2. To find the lag phase, log phase and stationary phase of A. baumannii growth 
(Rolfe et al., 2012; Hall et al., 2014). 
 Lag phase: a delay in time before bacterial exponential growth. 
 Log phase: Bacteria grow exponentially and at a constant rate. 
 Stationary phase: Bacteria cell death and division equal. 
 Death phase: Number of cells dying higher than cells dividing. 
 
3.9.2 Methodology 
Acinetobacter baumannii 19606 culti-loop was spread onto a fresh TSA plate and 
incubated at 37°C for 24 hours. After 24 hours, 2-3 colonies were removed from the 
plate using a wire loop and two universals containing sterile TSB were inoculated and 
incubated at 37°C overnight. Four blank controls were also made by removing 1ml 
sterile TSB from each conical flask and pipetted into 1ml plastic cuvettes. 
Using Equation 1 (Section 3.4.1), a calculated volume of inoculated overnight broth was 
removed and added to three conical flasks containing sterile TSB to give a final 
absorbance of 0.01 at a wavelength of 590nm in a final volume of 250ml. 
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The inoculation of each conical flask was staggered by 15 minutes before incubation at 
37°C in a shaker incubator set at 140 rotations per minute (rpm). An initial reading was 
taken at 0 minutes then at every hour for 30 hours. 
At each hour, 1ml was pipetted from the conical flask and transferred to a cuvette and 
the absorbance was measured at 590nm against the blank of TSB made from the 
corresponding conical flask. Three measurements were taken and an average 
calculated. If the reading was above 1 the solution was diluted down using sterile TSB 
and the resulting absorbance value was calculated based on the dilution ratio.  
After measuring the absorbance, a further 1ml was removed from the conical flask and 
pipetted into a glass universal containing 9ml ¼ strength Ringer’s solution. A serial 10-
fold dilution was completed to a chosen dilution for each hour, as shown in Section 8.2. 
100 µl was removed from the three highest serial dilutions and pipetted onto TSA and 
spread using sterile L-shaped spreaders. These plates were incubated at 37°C for 24 
hours. For the control, 1ml was removed to measure the absorbance and 100 µl was 
directly pipetted onto TSA and spread. 
After incubation, the colonies on each petri dish (three per hour) were visually counted 
and the number of viable cells (CFU/ml) were calculated for all thirty hours. A 
calibration of absorbance against cell number (CFU/ml) was then prepared. Graphs of 
absorbance and cell number (CFU/ml) against time for the 30 hour growth curve are 
shown in Section 4.2 
The spread plating procedure was also repeated at the start of each experiment to 
ensure the initial bacteria concentration was 5x105 CFU/ml.  
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3.10 Minimum Inhibitory Concentration (MIC) 
3.10.1 Objective 
The minimum inhibitory concentration (MIC) experiment was carried out to find the 
lowest concentration of antibiotic required to inhibit the growth of A. baumannii 
19606. The MIC was determined for each of the peptides, colistin sulphate, bicarinalin 
and BP100, using the following method (Wiegand et al., 2008; Eucast, 2003). 
 
3.10.2 Methodology 
A glass universal containing 10ml of sterile TSB was inoculated by taking 2-3 colonies 
of A. baumannii from a streaked TSA plate which had been incubated for 24 hours at 
37°C. This universal was incubated overnight at 37°C. Using the method described in 
Section 3.4.1, a glass universal containing 1x106 CFU/ml of A. baumannii in TSB was 
prepared. 
The peptides were prepared using the method described in Section 3.4.2. The solution 
was sterilised by filtering through a 0.2µm filter into sterile microtubes. Colistin 
sulphate was stored at 4°C while bicarinalin and BP100 were stored at -18°C. 
To produce a 2-fold serial dilution of antimicrobial peptide, 50 µl of sterile TSB was 
initially added to 12 wells of three rows of a 96 well plate. 50 µl of peptide, at a stock 
concentration of 1024µg/ml, was added to well 1 and a two-fold dilution was made for 
each of wells 2 to 12. This was completed by, firstly mixing the TSB and the peptide 
solution in well 1, then pipetting 50 µl from well 1 into well 2 and mixing again. This 
was repeated until well 12 where the excess 50µl was removed and discarded. 
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50 µl of inoculated TSB, containing 1x106 CFU/ml of A. baumannii, was added to each 
well resulting in a peptide concentration in each well as shown in Table 3.10.1 and a cell 
density of 5x105 CFU/ml. This was repeated for two further rows of the same 96 well 
plate. 
Well Concentration of Antimicrobial Peptide ( µg/ml) 
1 256 
2 128 
3 64 
4 32 
5 16 
6 8 
7 4 
8 2 
9 1 
10 0.5 
11 0.25 
12 0.125 
Table 3.10.1- Antimicrobial peptide concentration (µg/ml) per well after two fold dilution and 
addition of bacterial inoculum. 
 
Growth controls were also prepared containing 50µl of TSB and 50 µl of inoculated TSB 
to make a cell density of 5x105 CFU/ml and a sterility control containing 100 µl sterile 
TSB. The plate was covered in Parafilm to minimise evaporation and incubated at 37°C 
and 140rpm in a shaking incubator for 24 hours. After 24 hours, the wells were 
observed and turbid and clear wells were recorded. The lowest concentration of 
peptide where the well was visibly clear was recorded as the MIC. 
This entire experiment was repeated a further two times on two separate 96 well plates 
to give a total of nine datasets. The results are shown in Section 4.3. 
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3.11 Minimum Bactericidal Concentration (MBC) 
3.11.1 Objective 
The minimum bactericidal concentration was defined as the lowest concentration of 
antimicrobial peptide required to kill ≥99.9 % of A. baumannii cells (Eucast, 2003; 
Wiegand et al., 2008). After recording the MIC, the MBC for each peptide was 
determined by the plate spread method as described below. 
 
3.11.2 Methodology 
After recording the MIC, 100 µl was removed from each clear well and pipetted onto 
TSA and spread using sterile L-shaped spreaders. These plates were incubated at 37°C 
for 24 hours. After incubation, the number of colonies grown on the plates were 
counted and the lowest concentration where there was no growth observed on the 
plate was recorded as the MBC. This was carried out after each MIC test and therefore 
carried out 3 times. This experiment was repeated two further times to give a total of 
nine datasets. The results are shown in Section 4.4. 
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3.12 Minimum Biofilm Inhibitory Concentration (MBIC) 
3.12.1 Objective 
The minimum biofilm inhibitory concentration (MBIC) is defined as the lowest 
concentration of antimicrobial peptide that caused 90 % inhibition of A. baumannii 
biofilm formation (Gopal et al., 2014). Biofilm formation was quantified using the stain 
crystal violet method. 
Crystal violet or gentian violet stains the bacterial cells by binding to components of the 
bacterial cell wall such as lipopolysaccharides and peptidoglycan. Crystal violet 
dissolved in water absorbs light at 590nm (National Centre for biotechnology 
Information, 2015). A photo spectrometer at this wavelength was used to quantify the 
amount of crystal violet present.  
 
3.12.2 Methodology 
A 96 well plate containing a two-fold dilution of peptide with 5x105 CFU/ml A. 
baumannii was set up as described for the MIC test in Section 3.10. 
The plate was covered in Parafilm and incubated for 24 hours at 37°C  and 140rpm. 
After 24 hours, under aseptic conditions, the wells were emptied onto absorbent paper. 
The wells were washed three times with ¼ strength Ringer’s solution and air dried for 
1 hour in ambient room temperature (22°C).  
1 % crystal violet solution was prepared, in distilled water, and added to each well and 
left at room temperature for 10 minutes. The wells were emptied by pipetting onto 
absorbent paper, washed three times with distilled water, and air dried for 30 minutes 
at 37°C. 
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The stain was solubilised with 100 µl of 96 % ethanol (in distilled water). The plate 
was covered in Parafilm and shaken at 140rpm for 30 minutes. Using a 
spectrophotometer, 2 µl was removed from a well and the absorbance of the solution 
was measured at 590nm compared to a blank of 96 % ethanol. Three samples were 
taken from each well which were read twice to give six readings for each well. This was 
completed for all three rows. The experiment was repeated once more to give a dataset 
of 36 readings for each concentration. 
The percentage of biofilm inhibition was calculated using Equation 3 below: 
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟑: (1 − (
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (@590𝑛𝑚) 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑤𝑖𝑡ℎ 𝑡𝑒𝑠𝑡 𝑎𝑔𝑒𝑛𝑡
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (@590𝑛𝑚 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
))  x 100 
The results are shown in Section 4.5. 
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3.13 Biofilm Removal Assay 
3.13.1 Objective 
In this experiment, biofilms are grown then the reduction of biofilms (dead or alive) 
after treatment with increasing concentrations of each peptide is investigated. This 
contrasts with the preceding MBIC experiment that investigates the inhibition to 
biofilm growth for each peptide.  
24 hour biofilms were grown and then subjected to a range of peptide concentrations 
for 24 hours. The biofilm present in the well was quantified with crystal violet staining 
as previously described in Section 3.12 (Song et al., 2015; Dosler and Karaaslan, 2014).  
 
3.13.2 Methodology 
24 hour biofilms of A. baumannii were grown in 3 rows of 12 wells of the 96-well plate 
by adding 50 µl sterile TSB and 50 µl of inoculated TSB with 1x106 CFU/ml. The plate 
was incubated at 37°C at 140rpm. 
On a separate 96 well plate (titration plate) a two-fold serial dilution was prepared 
with 75 µl of TSB and 75 µl of antimicrobial peptide stock at a concentration of 8192 
µg/ml using the same method described in Section 3.10. 
The wells containing biofilm were washed three times with 150 µl ¼ strength Ringer’s 
solution. 75 µl sterile TSB was then added to each well. 75 µl from the titration plate 
containing a specific concentration of peptide was added to the corresponding well on 
the test plate. This resulted in each well containing 150 µl of TSB, which ensured the 
biofilm was completely submerged, and the test wells containing a two-fold serial 
dilution of antimicrobial peptide with concentrations shown in Table 3.13.1 below. 150 
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µl sterile TSB was added to the negative control wells. The plate was covered in 
Parafilm and incubated for 24 hours at 37°C and 140rpm in a shaker incubator. 
Well 
Concentration of Antimicrobial Peptide 
( µg/ml)  
1 2048 
2 1024 
3 512 
4 256 
5 128 
6 64 
7 32 
8 16 
9 8 
10 4 
11 2 
12 1 
Table 3.13.1- Antimicrobial peptide concentration for each well after a twofold-serial dilution. 
 
After 24 hours, the wells were emptied by tipping onto absorbent paper. The wells 
were washed three times with 200 µl ¼ strength Ringer’s solution and air fixed for 1 
hour under aseptic conditions.  
The percentage of biofilm removal was quantified by measuring the absorbance after 
applying crystal violet stain as follows. 100 µl of 1 % crystal violet solution in water 
was added to each well and left at room temperature for 10 minutes. The wells were 
emptied by tipping and washed three times with 150 µl distilled water and air dried at 
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37°C for 30 minutes. The stain was solubilised with 100 µl 96 % ethanol in a shaker 
incubator set at 140rpm for 30 minutes.  
The quantification of crystal violet was carried out using the same method as described 
in Section 3.12.  
This procedure was repeated for all three rows. The entire experiment was repeated 
once to give a total of 36 readings for each concentration. 
Equation 3 (Section 3.12) was used to ascertain the percentage biofilm reduction in the 
presence of the different antimicrobial peptide concentrations. The results are shown 
in Section 4.6. 
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3.14 Atomic Force Microscope 
3.14.1 Objective 
Using previously published methods (Alves et al., 2010; Domingues et al., 2014) the 
AFM was used to obtain 3D images of A. baumannii cells to analyse the surface 
topography and quantify the cell surface roughness and area when the cells are 
subjected to concentrations of peptides that equated to ½ MBC, MBC and 2xMBC for 
each peptide. These concentrations were based on results of the MBC experiment as 
described in Section 4.4. 
 
3.14.2 Methodology 
A 150 µl suspension containing inoculated TSB with an A. baumannii cell density of 
5x105 CFU/ml and peptide concentration as shown in Table 3.14.1 was prepared using 
methodology described in Section 3.10. A negative control containing 150 µl of A. 
baumannii at 5x105 CFU/ml was also prepared. 
The concentrations used for each peptide were based on the results of the MIC and 
MBC results as shown in Sections 4.3 and 4.4. The plate was incubated at 37°C and 
140rpm for 2 hours. 
  
71 
Antimicrobial Peptide Concentration Tested ( µg/ml) 
Colistin sulphate 
0.25 
0.5 
1 
Bicarinalin 
2 
4 
8 
BP100 
2 
4 
8 
Table 3.14.1- Concentrations of colistin sulphate, bicarinalin and BP100 used for AFM 
investigation. 
 
After 2 hours the solution was pipetted onto a poly-L-lysine slide and left at 
ambient room temperature (21±2°C) for 20 minutes. The slide was then rinsed by 
pipetting distilled water from the top of the slide and letting it run down, washing 
the surface. The slide was left to air dry for 20 minutes and then analysed using a 
Bruker Bioscope Catalyst Atomic Force Microscope (AFM) mounted on top of the 
Nikon Eclipse TE2000-S microscope. Bruker Atomic Force Microscope ScanAsyst-
air tips were used with the following characteristics:  
 Cantilever tip height-650nm,  
 Cantilever length-115µm,  
 Cantilever width-25µm,  
 Resonance frequency (F0)-70kHz,  
 Spring constant (k)-0.4N/m. 
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Images of the cells were obtained using the software program ‘NanoScope 9’ with an 
area of 4µm2 at a scan rate of 0.5Hz and 256 lines. The surface roughness and surface 
area of five selected bacterial cells were calculated using the Gwyddion SPM (scanning 
probe microscopy) software program (Necas and Klaptek, 2012). 
The image was firstly height levelled by a setting a plane through three points. A height 
threshold was produced to form a mask that discriminated the bacterial cell from the 
rest of the image. This meant that only the bacterial cell was analysed and not the glass 
slide. The RMS (root-mean-squared) calculation was used to analyse the surface 
roughness of the bacterial cell. The surface area of each of these cells was also 
quantified. 
The results are shown in Section 4.7 
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3.15 Scanning Electron Microscope 
3.15.1 Objective 
The SEM was used to visualise the A. baumannii biofilm grown on the surface of the 
polystyrene pegs of the Nunc-TSP Screening Plate Lid.  
The biofilm was grown for 24 hours and then subjected to four different 
concentrations, 1, 10, 100, 1000 µg/ml AMP for 24 hours. These concentrations were 
chosen based on biofilm removal results (Section 4.6).The biofilm was then fixed and 
prepared for SEM visualisation. 
 
3.15.2 Methodology 
Biofilms of A. baumannii were grown in 150 µl TSB in four wells of three rows of a 96-
well plate as described in Section 3.13 with the addition of a Nunc-TSP Screening Plate 
Lids lid containing polystyrene pegs which protruded down into the broth. Two 
negative controls were produced by pipetting 75 µl inoculated broth and 75 µl sterile 
TSB into a further two wells. 150 µl of sterile TSB was pipetted into two further wells 
allocated for sterility controls. The plate was covered in Parafilm and incubated at 37°C 
and 140rpm for 24 hours. 
After 24 hours, the pegs were washed by submerging the plate lid in 200 µl of sterile ¼ 
strength Ringer’s solution and leaving for 2 minutes. This was repeated twice more. 
Each well was then filled with 100 µl sterile TSB 
An antimicrobial challenge plate was prepared in a similar method described for the 
titration plate in Section 3.13. The challenge plate had four wells for each peptide, 
colistin sulphate, bicarinalin and BP100, containing peptide concentrations as shown in 
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Table 3.15.1. 200 µl sterile TSB was added to the negative control and sterility control 
wells. The plate lid was placed onto this challenge plate, covered in Parafilm, and 
incubated at 37°C and 140rpm for 24 hour.  
 
Well 
Concentration of antimicrobial peptide 
( µg/ml) 
1 1 
2 10 
3 100 
4 1000 
5 Negative Control 
6 Sterility Control 
Table 3.15.1- Concentration of antimicrobial peptide used in SEM investigation 
 
After 24 hours the pegs were washed by submerging the plate lid in 250 µl of sterile ¼ 
strength Ringer’s solution and leaving for 2 minutes. This was repeated twice more. 
0.1M sodium cacodylate buffer was made up by dissolving 1g in 40ml of distilled water. 
1M hydrochloric acid was added to the solution to give a pH reading of 7.2. Distilled 
water was added to give a final volume of 62.5ml. The plate pegs were then submerged 
in this solution for 3 minutes. 
2.5 % glutaraldehyde was prepared by mixing 5ml 25 % glutaraldehyde solution with 
45ml distilled water. The plate lid was placed onto the buffer in a 96 well plate, covered 
in Parafilm, and left at ambient temperature (21 ±2°C) for 40 minutes. The plate lid 
was then removed and washed in a 96 well plate containing 275 µl of distilled water in 
each well for 2 minutes. This was repeated once more. The biofilms were then 
dehydrated by placing into 2 plates containing 275 µl 50 % methanol, 2 plates 
containing 70 % methanol and finally 2 plates containing 100 % methanol. The plate lid 
was left in each solution for 2 minutes. The pegs were then left to dry for 4 days. 
75 
The pegs were then removed from the plate lid with flamed pliers and forceps and 
mounted onto 0.5in aluminium specimen stubs, fixed on carbon tabs. After mounting, 
the carbon tabs were painted with graphite and the pegs were coated with 
approximately 15-20nm of platinum. The pegs were visualised using a FEI Quanta FEG 
650 Scanning Electron Microscope at the Leeds Electron Microscopy & Spectroscopy 
Centre, University of Leeds. Images were visualised at 5000x, 10,000x, 20,000x, and 
30,000x magnification. Due to a time constraint for 8 hours three concentrations for 
each peptide, 1, 10, 100 µg/ml were visualised. The results are shown in Section 4.8. 
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3.16 Confocal Laser Scanning Microscope (CLSM) 
3.16.1 Objective 
The Leica TCS SP8 Confocal Microscope was used to analyse the structure of the biofilm 
and quantify the biofilm parameter bio-volume (µm3), defined as the amount of space 
or biomass occupied by a biofilm in a constant area (Harrison et al., 2006; Yerly et al., 
2007). 
The analysis was carried out by staining the biofilm with the fluorescent stain, SYTO9, 
and creating a Z stack of the biofilm by taking optical slices of the biofilm at 0.5µm 
intervals.  
 
3.16.2 Methodology 
A glass universal containing TSB, with a cell density of 1x106 CFU/ml, was prepared as 
discussed in Section 3.4.1. 150 µl of newly inoculated TSB was pipetted into 5 wells of 
an 8 chambered #1.0 borosilicate coverglass system. A further 150 µl of sterile TSB was 
added to each of these wells and 300 µl added to well 6 as a sterility control. The 
chambered coverglass was covered in Parafilm and incubated at 37°C and 140rpm for 
24 hours. After 24 hours, the wells were washed by removing the TSB and pipetting 
350 µl ¼ strength Ringer’s solution into the well and then removing the solution. The 
Ringer’s solution was added and removed a further two times. 
Four of the wells were filled with sterile TSB and a calculated concentration of 
antimicrobial peptide was added, using Equation 2 (Section 3.4.2), to give a final 
volume of 400 µl. The concentrations of peptide in each well are shown in the Table 
3.16.1 below. 400 µl of sterile TSB was pipetted into well 5, which was allocated for the 
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negative control, and sterility control. The chambered coverglass was covered with 
Parafilm and incubated at 37°C and 140rpm for 24 hours. 
Well Concentration of antimicrobial µg/ml 
1 1 
2 10 
3 100 
4 1000 
5 Negative Control 
6 Sterility Control 
Table 3.16.1- Concentration of antimicrobial peptide used in CLSM investigation. 
 
The wells were washed 3 times with sterile ¼ strength Ringer’s solution. The stain 
SYTO9 was prepared. 1ml microtubes containing concentrations of 6.7µM SYTO9 were 
prepared from the stock solutions of 3.34mM from BacLight Live/Dead staining, 
(Harrison et al., 2006) using Equation 4 below: 
 
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟒:         𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝐹𝑎𝑐𝑡𝑜𝑟 =
𝑂𝑟𝑔𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝐹𝑖𝑛𝑎𝑙 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑠 𝑅𝑒𝑞𝑢𝑖𝑟𝑒𝑑
 
 
SYTO9 was prepared by adding 3 µl of stain to 997 µl of Mili-Q water (18.2Ω) and 
stored at 4°C in the dark. 
Before use SYTO9 was vortexed at 800rpm for 15 seconds and 250 µl was pipetted into 
each well. The chamber was covered with silver foil to create dark conditions and 
incubated at 30°C for 30 minutes. The excess stain was rinsed out of the wells using 
250 µl of ¼ strength Ringer’s solution twice and a final volume of 200 µl ¼ strength 
Ringer’s solution was added to each well and the chamber was visualised under the 
CLSM. The biofilm was observed using the 40x using the 488nm PMT2 laser and an 
emission wavelength range of 490nm-515nm. The results are shown in Section 4.9 
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Biofilm bio-volume was quantified using BITPLANE Imaris x64 Version 8.1.2 (Bitplane, 
2015). 
 
3.17 Statistical Methods 
The program IBM SPSS Statistics 21 was used for the statistical analysis of MBIC 
(Section 3.12), biofilm removal assay (Section 3.13), surface roughness and area of 
bacteria cell surface visualised on the AFM (Section 3.14) and bio-volume quantified by 
BITPLANE Imaris software using images taken by the CLSM (Section 3.16). 
The samples t-test was used to find if there was a statistical difference of 95% (p≤0.05) 
which was considered as statistically significant or 99% (p≤0.01) which was 
considered highly significant between the results from each peptide concentration and 
the negative controls. 
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4 Results 
4.1 The Identification of A. baumannii 
4.1.1 Colony Morphology and Gram Stain 
A. baumannii 19606 colonies were grown using the methodology described in Section 
3.5. The colonies are shown in Figure 4.1.1 after being streaked on TSA. Figure 4.1.2 
illustrates the individual A. baumannii cells at a magnification of 40x under a light 
microscope after Gram staining, as described in Section 3.5. The colony morphology 
and Gram stain results are presented in Table 4.1.1.  
 
 
Figure 4.1.1-Streaked A. baumannii 19606 colonies after 24 hour incubation at 37°C. 
 
 
 
 
Single 
Colonies 
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Description Observation 
Form of colony Circular 
Size of colony (diameter) Small (~1mm) 
Margin of colony Entire/even 
Pigmentation of colony Pale yellow 
Opacity Opaque 
Elevation Flat 
Surface Smooth, glistening 
Consistency/Texture Moist 
Gram stain Gram-negative (pink-red cells) 
Shape of Cell Cocci-bacilli/short rods 
Length of Cell 2-2.5µm 
Width of Cell 1-1.5µm 
Table 4.1.1-Description of A. baumannii colonies on TSA plate; after 24 hour incubation 
at 37°C and light microscope analysis of cells after Gram-staining. 
 
 
Figure 4.1.2-Gram stain of A. baumannii: coccus-bacillus shaped cells; stained pink/red indicate 
Gram negative cell walls (magnification-40x). 
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4.1.2 Analytical Profile Index 20NE 
The API20NE test was used in the identification of Gram negative non-
Enterobacteriaceae (Al Jarousha et al.,2009; BioMérieux, 2015). The results of this test 
are shown in Sections 4.1.2, 4.1.3 and 4.1.4. 
After 24 hours, the strip was analysed for growth and colour changes in the cupules, 
using the results table supplied with the API 20NE test (Section 8.1). The results of the 
first eight tests are shown in Figure 4.1.3 and described below: 
 The potassium nitrate (NO3) cupule tested the ability to convert nitrates into 
nitrites. After the addition of the reagents NIT 1 and NIT 2, the cupule remained 
colourless indicating A. baumannii does not reduce nitrates to nitrites. To 
investigate if this was a false negative result, due to the formation of nitrogen, 
zinc powder reagent was added to the cupule and within 5 minutes the cupule 
turned pink/red. This colour change indicated the presence of nitrates, which 
had not been converted by A. baumannii. The NO3 cupule test was recorded as a 
negative result. 
 The L-tryptophan (TRP) cupule tested the ability to produce indole from the 
amino acid tryptophan. With the addition of JAMES reagent the cupule 
remained colourless indicating A. baumannii does not produce indole and a 
negative result was recorded. 
 The glucose (GLU) cupule contained glucose and tested the ability to ferment 
glucose in anaerobic conditions. The cupule resulted in a negative colour 
change of blue indicating the inability of A. baumannii to ferment glucose after 
24 hours incubation.  
 The next three tests assessed the ability of A. baumannii to hydrolyse Arginine 
(ADH), Urea (URE) and Aesculin (ESC); all three cupules remained yellow after 
24 hours and were recorded as negative results.  
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 The Gelatin test (GEL) assessed the ability to hydrolyse gelatin with the enzyme 
protease. There was no pigment diffusion seen within the cupule and a negative 
result was recorded.  
 The final and eighth test assessed the ability of A. baumannii to hydrolyse 4-
nitrophenyl-βD-galactopyranoside (PNPG); the cupule remained colourless and 
was recorded as a negative result. 
 
Figure 4.1.3-First 8 tests of API 20NE; after 24 hour incubation; NO3 after the addition of NIT1, 
NIT2 & Zinc powder and TRP after the addition of JAMES reagent. 
 
The strip was incubated for a further 24 hours at 37°C and the results are shown in 
Figure 4.1.4. The results are the same as the 24 hour incubation. 
 
 
Figure 4.1.4-First 8 tests of API20NE after 48 hour incubation. Note: Emptying and refilling with 
mineral oil of cupules NO3 and TRP. The results are consistent with the 24 hour incubation. 
 
The assimilation tests assessed the ability of A. baumannii to grow in the presence of 
the substrate in the cupule. The results of the twelve assimilation tests were recorded 
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after 24 hours and 48 hours; the 48 hour strip is shown as Figure 4.1.5, based on 
whether the cupules were turbid or clear. 
After the 24 hour incubation period, the following tests had turbid wells indicating 
bacterial growth and were recorded as positive results: 
 Arabinose (ARA) 
 Capric acid(CAP) 
 Adipic acid (API) 
 Malic acid (MLT) 
 Trisodium citrate (CIT) 
 Phenylacetic acid (PAC) 
 
The following tests had clear cupules indicating no growth and were recorded as 
negative results: 
 Glucose (GLU) 
 Mannose (MNE) 
 Mannitol (MAN) 
 N-acetyl glucosamine (NAG) 
 Maltose (MAL) 
 Potassium gluconate (GNT) 
 
The twelve assimilation tests were read again after 48 hours and their results recorded 
based on turbid or clear cupules. The results at 48 hours were identical as at 24 hours. 
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Figure 4.1.5-Assimilation Tests of API 20NE Strip after 48 hours incubation. Note turbid results 
for ARA, CAP, ADI, MLT, CIT, PAC cupules; the other cupules remained clear. 
 
This test confirmed the identification of A. baumannii/calcoaceticus with 99.9% 
confidence (Section 4.1.4). 
  
Turbid Wells 
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4.1.3 Oxidase Test 
The oxidase test was used to test for the presence of cytochrome C oxidase as described 
in Section 3.8. A dark blue/ purple colour change would indicate a positive result. 
As shown in Figure 4.1.6, A. baumannii is oxidase negative as no colour change was 
observed within 10 seconds. This was compared to the dark blue/purple colour of 
positive control, Pseudomonas aeruginosa, and the colourless sample of the negative 
control, Klebsiella pneumoniae. 
 
 
Figure 4.1.6- Oxidase Test Result showing positive control of Pseudomonas aeruginosa (A), A. 
baumannii (B) and negative control Klebsiella pneumoniae (C). 
 
4.1.4 Numerical Profiling of A. baumannii 
The identification of A. baumannii was completed by numerical profiling, by analysing 
the results with the biomerieux software (Biomerieux, 2015). The twenty tests on the 
API 20NE strip and oxidase test were split into seven groups of three. Using a results 
sheet, a 7-digit number was obtained by  concatenating  the numbered values of 1, 2 
and 4 corresponding to positive reactions within the group of three, as shown in the 
Figure 4.1.7. 
 
A B
V 
 A 
 A 
C
V 
 A 
 A 
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Figure 4.1.7-API20NE Numerical Profiling for the Identification of A. baumannii 
 
The 7-digit number, 0001073, was entered into apiweb which confirmed the 
identification of the A. baumannii group with 99.9% identification confidence as shown 
in Figure 4.1.8 (Biomerieux, 2015). The complementary test of growing a spread plate 
at 44°C was carried out and growth was observed indicating the presence of A. 
baumannii species (Saugar et al., 2006; Vaneechoutte et al., 2011). 
 
 
Figure 4.1.8-apiweb identification of A. baumannii confirming identification with 99.9% 
confidence with number 0001073.  
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4.2 30 Hour Growth Curve of A. baumannii 19606 
The objectives and methodology of the 30 hour growth curve are described in Section 
3.9. Figure 4.2.1 shows the absorbance at 590nm over 30 hours. The initial absorbance, 
at hour 0, was 0.01, the lowest reading the photometer was able to read. It shows the 
lag phase lasted for about 1 hour with an absorbance of 0.034, averaged over the three 
test samples. At the second hour the absorbance had risen by 400%. The absorbance 
then increased each hour following an approximately linear relationship for the 
remainder of the experiment. 
 
Figure 4.2.1- Graph showing the absorbance of TSB containing A. baumannii over 30 hours. 
Results from all three tests samples are used to construct the standard deviation bars at each 
hour. 
 
Figure 4.2.2 shows the cell count (CFU/ml) against time. This graph shows the lag 
phase of A. baumannii growth lasting about 1 hour which is consistent with the results 
shown in Figure 4.2.1. The growth is approximately exponential to 26 hours indicating 
the log phase (Section 3.9.1). The experiment was not extended sufficiently to confirm 
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the stationary phase but it may starts at about 26 hours as indicated by the CFU/ml 
plateau. 
 
 
Figure 4.2.2-CFU/ml per hour on a logarithmic scale. Results from all three tests samples are 
used to construct the standard deviation bars at each hour. 
 
The absorbance for a specific viable cell count (CFU/ml) was found by plotting the 
absorbance against the CFU/ml. The absorbance at the start was 0.01 and the average 
CFU/ml at this absorbance was 1x107 CFU/ml. This absorbance value was used in 
Equation 1 in the absorbance calculation described in Section 3.4.1. 
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4.3 Minimum Inhibitory Concentration (MIC) 
The MIC experiment was carried out to find the lowest concentration of antibiotic 
required to inhibit the growth of A. baumannii following the methodology described in 
Section 3.10 (Eucast, 2003; Wiegand et al., 2008). The clear wells indicate no growth 
and the turbid wells indicate growth. The lowest concentration of peptide in a well 
which was clear was recorded as the MIC. The MIC for colistin sulphate was 0.5 µg/ml, 
4 µg/ml for bicarinalin and 4 µg/ml for BP100 as shown in Figures 4.3.1, 4.3.2 and 4.3.3.  
In Figures 4.3.1-4.3.3, rows A, B and C are identical test rows. Negative controls are in 
wells D1-3 and sterility controls in wells D10-12. All of the growth controls were turbid 
indicating growth and the sterility controls remained clear indicating no contamination 
to the assay. 
Figure 4.3.1 displays the MIC results for colistin sulphate. Turbid wells were observed 
for wells 11 and 12 from all test rows. The MIC was determined to be the colistin 
sulphate concentration in Column 10 which was 0.5µg/ml. 
 
Figure 4.3.1-96 well plate showing minimum inhibitory concentration of colistin sulphate; MIC is 
0.5 µg/ml as shown with clear broth in well 10 in all three test rows. Note: Concentration range: 
Well 1: 256 µg/ml -Well 12:0.125 µg/ml. 
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Figure 4.3.2 displays the MIC results for bicarinalin. Turbid wells were observed for 
wells 8 to 12 from all test rows. The MIC was determined to be the bicarinalin 
concentration in Column 7 which was 4 µg/ml.  
 
 
Figure 4.3.2-96 well plate showing minimum inhibitory concentration of bicarinalin; MIC is 4 
µg/ml as shown with clear broth in well 7 in all three rows. Note: Concentration range: well 1: 
256 µg/ml to well 12: 0.125 µg/ml. 
 
Figure 4.3.3 displays the MIC results for BP100. Turbid wells were observed for wells 8 
to 12 from all test rows. The MIC was determined to be the BP100 concentration in 
Column 7 which was 4 µg/ml.  
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Figure 4.3.3-96 well plate showing minimum inhibitory concentration of BP100; MIC is 4 µg/ml 
as shown with clear broth in well 7 in all three rows. Note: Concentration range: Well 1: 256 
µg/ml -Well 12: 0.125 µg/ml. 
 
The recorded MIC is a maximum as, due to the two-fold dilution technique, the 
inhibition of growth would be between the last turbid well and the first clear well. For 
example, colistin sulphate had a MIC of 0.5 µg/ml, recorded for the first clear well. The 
MIC lies between 0.25 µg/ml (turbid well) and 0.5 µg/ml (clear well). The MICs for 
bicarinalin and BP100 both are between 2 µg/ml and 4 µg/ml. A more accurate MIC 
could be derived by a further detailed analysis of peptide concentrations within the 
range (Section 5.2). 
 
Peptide 
Minimum Inhibitory 
Concentration (µg/ml) 
Minimum Inhibitory 
Concentration (µmol/l) 
Colistin sulphate 0.5 0.43 
Bicarinalin 4 1.8 
BP100 4 2.8 
Table 4.3.1- MIC for colistin sulphate, bicarinalin and BP100.  
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In Table 4.3.1 the MIC according to molar concentration is also tabulated. The molar 
concentration has been calculated from the molecular weights of each peptide. 
Bicarinalin has the highest molecular weight at 2213.78 g/mol of the peptides tested 
with colistin sulphate weighing 1155.4 g/mol and BP100 weighing 1420 g/mol (Rifflet 
et al., 2012; Alves et al., 2010; Velkov et al., 2010).  
 
4.4 Minimum Bactericidal Concentration (MBC) 
The minimum bactericidal concentration was defined as the lowest concentration of 
antimicrobial peptide required to kill ≥99.9 % of A. baumannii cells (Eucast, 2003; 
Wiegand et al., 2008). The clear wells from the MIC experiment were spread onto TSA 
plates. The methodology is described in Section 3.11. The lowest concentration of 
peptide where there was no growth observed on the plate was recorded as the MBC. In 
Table 4.4.1, the MBC for each peptide is shown. 
Similar to the MIC experiment results as described in Section 4.3, the MBC recorded is a 
maximum and could be between the peptide concentrations tested. For colistin 
sulphate, the solution from wells 1-10, where well 10 had 0.5 µg/ml of peptide, were 
spread as they were clear. No growth was observed on the plate for 0.5 µg/ml so this 
was recorded as the MBC; the true MBC would be between 0.5 µg/ml and 0.25 µg/ml 
where there was growth observed in the well. 
Peptide 
Minimum Bactericidal 
Concentration (µg/ml) 
Minimum Bactericidal 
Concentration (µmol/l) 
Colistin sulphate 0.5 0.43 
Bicarinalin 4 1.8 
BP100 4 2.8 
Table 4.4.1- MBC for colistin sulphate, bicarinalin and BP100. 
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4.5 Minimum Biofilm Inhibitory Concentration (MBIC) 
The minimum biofilm inhibitory concentration (MBIC) was defined as the lowest 
concentration of antimicrobial peptide that caused 90 % inhibition of A. baumannii 
biofilm formation (Gopal et al., 2014). Biofilm formation was quantified using the stain 
crystal violet method as described in Section 3.11. 
Figure 4.5.1 shows 90 % of biofilm formation was inhibited when A. baumannii cells 
were subjected to concentrations of 0.5 µg/ml colistin sulphate and 4 µg/ml of 
bicarinalin and BP100. 
 
 
Figure 4.5.1-MBIC for colistin sulphate, bicarinalin and BP100. Estimated MBIC values are 
Colistin sulphate 0.5µg/ml, bicarinalin 4µg/ml and BP100 4µg/m. All results were p<0.01 apart 
from BP100 at 2 µg/ml. 
 
A sample T test (Section 3.17) was carried out to test the statistical significance 
between each concentration of peptide and the negative control. All the results for 
colistin sulphate, bicarinalin and BP100 were found to be highly significant at p<0.01 
apart from the result for BP100 at 2 µg/ml which was not statistically significant.  
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The data shows that for all peptides, biofilm formation was inhibited by more than 90 
% for concentrations at and above the peptide’s respective MBC (Section 4.4). 
 
4.6 Biofilm Removal Assay 
The amount of the biofilm was quantified by crystal violet staining. The percentage of 
biofilm removed by the peptide was calculated by comparing the biofilm grown (as the 
negative control, containing a theorised 100% of biofilm) with the amount of biofilm 
remaining after 24 hours after being subjected to a concentration of peptide in the 
range of 1 to 2048 µg/ml. Biofilms of A. baumannii were grown for 24 hours in separate 
wells of 96 well plates and then subjected to a concentration range of each of the 
antimicrobial peptides. The methodology is described in detail in Section 3.13 and the 
results are shown below. 
One set of representative plates for each of the three peptides are shown in Figures 
4.6.1, 4.6.2 and 4.6.3. There is a noticeable lighter shade of purple from the crystal violet 
staining in the BP100 plate (Figure 4.6.3) from concentrations 256 µg/ml to 2048 
µg/ml compared to bicarinalin (Figure 4.6.2) and colistin sulphate (Figure 4.6.1) 
suggesting more biofilm has been removed.  
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Figure 4.6.1- Well plate showing biofilm removal by colistin sulphate; peptide concentration from 
2048µg/ml to 1µg/ml. 
 
 
 
 
Figure 4.6.2- Well plate showing biofilm removal by bicarinalin; peptide concentration from 
2048µg/ml to 1µg/ml. 
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Figure 4.6.3-Well plate showing biofilm removal by BP100; peptide concentration from 
2048µg/ml to 1µg/ml. 
 
The crystal violet stain was quantified using a spectrophotometer at 590nm. The 
results were then compared to an average of the negative control wells which contained 
a theoretical 100% biofilm. The lowest concentration of antimicrobial peptide tested 
was 1 µg/ml and the maximum was 2048 µg/ml. The results are shown in Figure 4.6.4. 
The results indicate that bicarinalin and BP100 exhibited anti-biofilm activity which 
was optimal for bicarinalin at 128 µg/ml and BP100 at 2048 µg/ml. Statistical analysis 
of all the concentrations for all three peptides, compared against the negative control, 
was carried out using IBM SPSS 21 by the samples T-test. 
 Colistin sulphate at a concentration of 1 µg/ml removed 27 % of the biofilm. 
The eradication increased as the concentration increased until at 512 µg/ml 
colistin sulphate removed 52 % of the biofilm, the maximum eradication for all 
the concentrations tested. The eradication decreased marginally to 44% at the 
highest concentration tested of 2048 µg/ml compared to 512 µg/ml but this 
decrease was not statistically significant. 
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 Bicarinalin at 1 µg/ml removed 19% of biofilm and at 128 µg/ml, removed 70% 
of the biofilm. This concentration appeared optimal as there was no further 
increase above 128 µg/ml.  
 BP100 at 1 µg/ml concentration removed 15% of biofilm and at 128 µg/ml, the 
elimination was 54%. BP100 was better at eradicating more biofilm than 
colistin sulphate at concentrations at and above 128 µg/ml and better than 
bicarinalin from 256 µg/ml. While colistin and bicarinalin percentage removal 
plateaued, the percentage of biofilm reduced by BP100 continued to increase to 
the highest concentration tested of 2048 µg/ml where it had removed 95 % of 
the biofilm. This was nearly double that of colistin sulphate with 52%. 
 
.
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Figure 4.6.4-Percentage biofilm removed after being exposed to increasing concentrations of colistin sulphate, bicarinalin and BP100
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4.7 Atomic Force Microscope 
The AFM was used to visualise single cells after being subjected to the three peptides. 
The data obtained from the MIC and MBC experiments (Sections 4.3 and 4.4) were used 
to establish the peptide concentrations which were determined to be ½ MBC, MBC and 
2x MBC for each peptide. 
 
4.7.1 Colistin sulphate 
Images obtained with the AFM show A. baumannii cells when they had been subjected 
to 0 µg/ml, 0.25 µg/ml (½ MBC), 0.5 µg/ml (1xMBC), 1 µg/ml (2xMBC) of colistin 
sulphate for 2 hours (Figure 4.7.1).  
Image A is a control and shows an A. baumannii cell with no addition of colistin 
sulphate. This cell exhibits the uniform coccus-bacillus shape and a smooth cell surface 
with no visible pili or surface appendages.  
Image B shows a cell that has been subjected to 0.25 µg/ml (½ MBC) of colistin 
sulphate. The cell still has a recognisable coccus-bacillus shape as in the control but the 
surface shows evidence of morphological changes which may be pores or indents due 
to peptide activity. This specific image shows the cell starting to undergo binary fission 
indicating cells are still metabolically active and undergo cell division below the MBC 
concentration of peptide. 
Image C shows a cell which has been subjected to 0.5 µg/ml (MBC) of colistin sulphate. 
The cell shape has been severely disrupted by antimicrobial activity to the extent that 
the cocci-bacilli shape is no longer recognisable. There is also evidence of surface 
distortion.  
C 
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Image D shows an A. baumannii cell after being subjected to 1 µg/ml (2xMBC) of 
colistin sulphate. The AFM images clearly show that the cell surface has become 
extensively disrupted at concentrations equal or above the MBC of colistin sulphate.
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Figure 4.7.1- AFM Images: A. baumannii cells after being subjected to colistin sulphate; treatment for 2 hours with variable concentrations of colistin sulphate and 
fixed onto a glass slide coated with poly-L-lysine. Image A) Control no peptide, B) 0.25 µg/ml, C) 0.5 µg/ml, D) 1µg/ml. Images were 4µm2 and 256 lines at 0.5Hz
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The surface roughness was quantified by taking the root mean square (RMS) of the 
measurements from five cells. The mean was determined at colistin sulphate 
concentrations of 0.25 µg/ml (½ MBC), 0.5 µg/ml (1xMBC) and 1 µg/ml (2xMBC). A 
statistical analysis, using IBM SPSS 21 independent-samples T test, was carried out by 
comparing each peptide concentration against the control. The results are shown in 
Figure 4.7.2. 
The degree of statistical significance is indicated by the * symbols where * indicates 
high significance (p<0.05) and ** indicates very high significance (p<0.01).  
The negative control cells had an average cell roughness of 65nm with a value deviation 
of 8.9 nm. When the cells were subjected to 0.25 µg/ml colistin sulphate there was no 
significant change in the cell roughness. When the cells were subjected to a 
concentration of 0.5 µg/ml, the surface roughness increased to 136 nm (p ≤0.05). After 
the cells were exposed to 1 µg/ml concentration the surface roughness decreased to 
103nm (p ≤0.05) suggesting the destruction of the membrane. 
 
Figure 4.7.2- Surface roughness of cells after colistin sulphate treatment. Concentrations at 0.5 x, 
1 and 2 x MBC, compared to the control, treatment for 2 hours. * statistical significance (p< 
0.05), error bar indicates range of measurements from the 5 cell samples. 
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These results show that, at the MBC and above, the surface roughness of the cell 
significantly increases suggesting membrane disruption caused by the peptide.  
The cell surface area was also quantified in addition to surface roughness. Five cells 
were selected from each group subjected to 0.25 µg/ml, 0.5 µg/ml and 1 µg/ml colistin 
sulphate concentrations.  The surface area was calculated and values averaged; the 
results are shown in Figure 4.7.3. The control had an average surface area of 2.6 µm2. At 
0.25 µg/ml this increased to 4.12 µm2 (p<0.05). This decreased to 3.43 µm2 at 0.5 
µg/ml and 2.24 µm2 at 1 µg/ml, which is below the control average. 
 
 
Figure 4.7.3-Surface area of cells after colistin sulphate treatment. Concentrations at 0.5, 1 and 2 
x MBC, compared to the control, treatment for 2 hours. * Statistical significance (p< 0.05) 
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4.7.2 Bicarinalin 
In Figure 4.7.4, the images show A. baumannii cells when they had been subjected to 
concentrations 2 µg/ml (½ MBC), 4 µg/ml (1xMBC), 8 µg/ml (2xMBC) of bicarinalin 
for 2 hours.  
Image A is a control and shows an A. baumannii cell with the uniform coccus-bacillus 
shape and a smooth cell surface.  
Image B shows a cell that has been subjected to 2 µg/ml of bicarinalin. It still has a 
recognisable coccus-bacillus shape and smooth cell surface as seen in the control. 
Image C shows a cell which has been subjected to 4 µg/ml of bicarinalin. The cell shape 
is unrecognisable and shows some membrane swelling and the overall cell has shrunk. 
Image D shows a cell after being subjected to 8 µg/ml, similar to image C, the 
membrane has been severely disrupted and the cell has shrunk with membrane 
swelling. 
.
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Figure 4.7.4- AFM Images: A. baumannii cells after being subjected to bicarinalin; treatment for 2 hours with variable concentrations of bicarinalin and fixed onto a 
glass slide coated with poly-L-lysine. Image A) Control (no peptide), B) 2 µg/ml, C) 4 µg/ml, D) 8 µg/ml. Images were 4µm2 and 256 lines at 0.5Hz.
106 
The surface roughness of each cell was quantified using Gwyddion as explained in 
Section 3.14.1. The results are shown in Figure 4.7.5. 
The negative control cells had an average cell roughness of 64.9 nm with a value 
deviation of 8.9 nm. When the cells were subjected to 2 µg/ml of bicarinalin there was 
no significant change in the cell roughness. When the cells were subjected to 4 µg/ml 
the surface roughness increased to 139.9 nm (p ≤0.05). There was a decrease to 71.4 
nm in surface roughness as the cells were exposed to 8 µg/ml. 
 
 
Figure 4.7.5- Surface roughness of cells after bicarinalin treatment. Concentrations at 0.5 x, 1 and 
2 x MBC, compared to the control, treatment for 2 hours. * statistical significance (p< 0.05), 
error bar indicates range of measurements from the 5 cell samples. 
 
The surface roughness significantly increased when subjected to a peptide 
concentration equivalent to the MBC similar to the results for colistin sulphate. 
The cell surface area was quantified using five cells subjected to 2 µg/ml, 4 µg/ml and 8 
µg/ml and the results are shown in Figure 4.7.6. The control had a mean surface area of 
2.6 µm2. At 2 µg/ml this increased to 3.1 µm2 (p ≤0.01). The surface area decreased to 
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2.67 µm2 at 4 µg/ml and further to 1.91 µm2 at 8 µg/ml (p ≤0.05), which was less than 
the control area.  
 
 
Figure 4.7.6- Surface area of cells after bicarinalin treatment. Concentrations at 0.5, 1 and 2 x 
MBC, compared to the control, treatment for 2 hours. * Statistical significance (p< 0.05) 
** (p≤0.001) 
 
4.7.3 BP100 
In Figure 4.7.7, the images show A. baumannii cells when they had been subjected to 
concentrations 2 µg/ml (½ MBC), 4 µg/ml (1xMBC), 8 µg/ml (2xMBC) of BP100 for 2 
hours.  
Image A is a control and shows a cell exhibiting the uniform cocci-bacilli shape and a 
smooth cell surface.  
Image B shows a cell that has been subjected to 2 µg/ml BP100. This image shows the 
cell undergoing cell division but still has a smooth cell membrane and is cocci-bacilli 
shaped. 
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Image C shows a cell which has been subjected to 4 µg/ml of BP100. The cell shape has 
been severely disrupted by antimicrobial activity to the extent that the cocci-bacilli 
shape is no longer recognisable along with membrane swelling and blebbing.  
Image D shows a cell after being subjected to 8 µg/ml; the surface has been severely 
disrupted and the cell has shrunk. 
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Figure 4.7.7- AFM images of A. baumannii cells after being subjected to BP100 treatment for 2 hours and fixed onto a glass slide coated with poly-L-lysine. Image A) 
Control, B) 2 µg/ml, C) 4 µg/ml, D) 8 µg/ml. Images were 4µm2 and 256 lines at 0.5htz
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The surface roughness of each cell was quantified using Gwyddion as explained in 
Section 3.14.1. The RMS average of five cells at 2 µg/ml, 4 µg/ml and 8 µg/ml of BP100 
were quantified. A statistical analysis using IBM SPSS 21 independent-samples T test 
was completed by comparing each peptide concentration against the control. The 
results are shown in Figure 4.7.8. 
The negative control cells had an average cell roughness of 64.9 nm with a value 
deviation of 8.9 nm. At each of the concentrations tested, 2 µg/ml, 4 µg/ml and 8 µg/ml, 
there was no significant change (p >0.05) in the surface roughness when compared 
with the negative control. There was however a greater range of surface roughness as 
the peptide concentration increased with a value deviation of 11.1 nm at 2 µg/ml, 20.5 
nm at 4 µg/ml and 30.3 at 8 µg/ml. This suggests that there was a membrane 
disruption but for only some of the cells.  
 
 
Figure 4.7.8- Surface roughness of cells after BP100 treatment. Concentrations at 0.5 x, 1 and 2 x 
MBC, compared to the control, treatment for 2 hours. * statistical significance (p< 0.05), error 
bar indicates range of measurements from the 5 cell samples. 
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The cell surface area was also quantified using five cells subjected to 2 µg/ml, 4 µg/ml 
and 8 µg/ml; the results are shown in Figure 4.7.9. The control had a mean surface area 
of 2.6 µm2. At 2 µg/ml this increased to 3.1 µm2 (p ≤0.05). This remained at  3.1 µm2 at 
4 µg/ml and then decreased to 2.2 µm2 at 8 µg/ml. 
 
 
Figure 4.7.9- Surface area of cells after BP100 treatment. Concentrations at 0.5, 1 and 2MBC, 
compared to the control, treatment for 2 hours. * Statistical significance (p< 0.05) 
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4.8 Scanning Electron Microscope 
The SEM was used to visualize pre-formed 24 hour A. baumannii biofilms after being 
subjected to one of the three peptides for 24 hours at concentrations 1, 10, 100, 
1000µg/ml. These concentrations were selected based on the results from the biofilm 
removal assay (Section 4.6). 
 
4.8.1 Colistin sulphate 
A. baumannii biofilms were grown on polystyrene pegs for 24 hours and then subjected 
to a specific concentration of colistin sulphate (1, 10, 100, 1000µg/ml) for 24 hours and 
prepared for SEM visualisation as explained in Section 3.15. The biofilms were 
visualised at the magnifications 5,000x, 10,000x, 20,000x and 30,000x. The 5,000x and 
30,000x for the concentrations 1, 10, 100 µg/ml are shown in Figure 4.8.1. Due to the 
time available the samples subjected to 1000 µg/ml were not visualised. 
Image A shows a control sample; the biofilm was grown for 48 hours without the 
addition of any peptide. The image at 30,000x magnification shows the cells are normal 
in size and shape and there is evidence of some pili between cells. The 5,000x 
magnification insert shows the cells carpet the whole of the peg surface.  
Image B shows the biofilm which had been subjected to 1 µg/ml colistin sulphate, (2x 
MBC). At 30,000x magnification the cells have a smooth cell surface and uniform 
coccus-bacillus shape and multiple pili are seen between cells. At 5,000x, there are a 
few gaps in the biofilm. 
Image C shows the biofilm which has been subjected to 10 µg/ml of colistin sulphate, 
(20x MBC). At 30,000x magnification, a large proportion of the cells have shrunk and 
the shape disrupted. At 5,000x magnification there are significant gaps in the biofilm.  
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Image D shows the biofilm which has been subjected to 100 µg/ml of colistin sulphate 
(200x the MBC). Severe membrane disruption has caused nearly all the cells to shrink. 
In the image, there is also evidence of completely lysed cells or cytoplasmic remnants 
leaked from the cells. At 5,000x magnification there are significant gaps in the biofilm. 
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Figure 4.8.1- SEM images: A baumannii biofilms after being subjected to colistin sulphate, biofilms grown for 24 hours then treatment for 24 hours with variable 
concentrations of colistin sulphate. Image A) Control no peptide, B) 1 µg/ml, C) 10 µg/ml, D) 100 µg/ml. Large image at 30,000x magnification and insert at 5,000x 
magnification.
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4.8.2 Bicarinalin 
A. baumannii biofilms were grown on polystyrene pegs for 24 hours and then subjected 
to a specific concentration of bicarinalin (1, 10, 100 or 1000µg/ml) for 24 hours and 
prepared for SEM visualisation as explained in Section 3.15. The biofilms were 
visualised at the magnifications 5000x, 10000x, 20000x and 30000x. The images with 
5000x and 30000x magnification, for the concentrations 1, 10, 100 µg/ml are shown in 
Figure 4.8.2. 
Image A shows the control sample used and analysed in Section 4.8.1.  
Image B shows the biofilm which had been subjected to 1 µg/ml bicarinalin, (0.25x 
MBC). At 30,000x the cells have a smooth surface and uniform cocci-bacilli shape and 
multiple pili are seen between cells. At 5,000x, there are very small gaps in the biofilm 
but otherwise the cells carpet the peg. 
Image C shows the biofilm which has been subjected to 10 µg/ml of bicarinalin (2.5x 
MBC). At 30,000x magnification there is evidence of blebbing and minor membrane 
disruption. 
Image D shows the biofilm which has been subjected to 100 µg/ml of bicarinalin (25x 
MBC). Severe membrane disruption in all the cells can be seen and evidence of 
widespread cell lysis. At 5,000x magnification large and numerous gaps in the biofilm 
are seen. 
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Figure 4.8.2-SEM images: A baumannii biofilms after being subjected to bicarinalin, biofilms grown for 24 hours then treatment for 24 hours with variable 
concentrations of bicarinalin. Image A) Control no peptide, B) 1 µg/ml, C) 10 µg/ml, D) 100 µg/ml. Large image at 30,000x magnification and insert at 5,000x 
magnification 
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4.8.3 BP100 
A. baumannii biofilms were grown on polystyrene pegs for 24 hours and then subjected 
to a specific concentration of BP100 (1, 10, 100, 1000µg/ml) for 24 hours and prepared 
for SEM visualisation as explained in Section 3.15. The biofilms were visualised at the 
magnifications 5000x, 10000x, 20000x and 30000x. The 5000x and 30000x for the 
concentrations 1, 10, 100 µg/ml are shown in Figure 4.8.3. 
Image A shows the control sample used and analysed in Section 4.8.1. 
Image B shows the biofilm which had been subjected to 1 µg/ml BP100 (0.25x MBC). At 
30000x the cells have a smooth cell surface and uniform cocci-bacilli shape and 
multiple pili are seen between cells. At 5000x, there are very small gaps in the biofilm 
but otherwise the cells carpet the peg. 
Image C shows the biofilm which has been subjected to 10 µg/ml of BP100 (2.5x MBC). 
At 30000x magnification there is evidence of blebbing and minor membrane disruption 
with a few cells showing severe membrane disruption. 
Image D shows the biofilm which has been subjected to 100 µg/ml of BP100 (25x 
MBC). Severe membrane disruption in all the cells can be seen and evidence of pores 
through the membrane. At 5000x magnification there are large and numerous gaps in 
the biofilm. 
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Figure 4.8.3- SEM images: A baumannii biofilms after being subjected to BP100, biofilms grown for 24 hours then treatment for 24 hours with variable 
concentrations of BP100. Image A) Control no peptide, B) 1 µg/ml, C) 10 µg/ml, D) 100 µg/ml. Large image at 30,000x magnification, insert at 5,000x magnification. 
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4.9 Confocal Laser Scanning Microscope (CLSM) 
CLSM was used to visualise 48 hour A. baumannii biofilms after being subjected to one 
of the three peptides for 24 hours at concentrations 1, 10, 100, 1000µg/ml. These 
concentrations were selected based on the results from the biofilm removal assay 
(Section 4.6). The 40x magnification was used to visualise an area of 290µm2. Five 
samples were taken of each biofilm. A biofilm at each of the peptide concentrations and 
a control are shown where the SYTO9 stain has been fluoresced. 
 
4.9.1 Colistin sulphate 
SYTO 9 stains all cells whether they are living or dead. Image A shows the control 
sample used. From image B to E, the peptide concentration increased by 10-fold in each 
figure. The images show a reduction in the area of the biofilm as the peptide 
concentration increases. 
To quantify the decrease in biofilm as the colistin sulphate concentration increases, the 
bio-volume of the biofilm at each peptide concentration was calculated using 
BITPLANE Imaris software. The results are shown in Figure 4.9.2. The control had a 
bio-volume of 227,067 µm3 with a standard deviation of 8,668 µm3. At 1µg/ml and 
10µg/ml peptide concentrations, there was no significant difference compared to the 
control (p≤0.05). At 100µg/ml, the bio-volume was 163,427 µm3 (p≤0.01). The biofilm 
volume increased slightly to 171,070 µm3 at 1000 µg/ml (p≤0.05) but with no 
statistical difference (p>0.05). This represented a bio-volume reduction of 
approximately 25%. 
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Figure 4.9.1- CLSM images: A. baumannii biofilms after being subjected to colistin sulphate; grown for 24 hour in a chambered cover glass then subjected to a specific 
concentration of colistin sulphate for 24 hours. Biofilms were stained with SYTO 9 for visualisation. Colistin sulphate concentration in image A) Control (no 
peptide) B) 1 µg/ml, C) 10 µg/ml, D) 100 µg/ml, E) 1000 µg/ml
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Figure 4.9.2- Bio-volume (µm3) of biofilm at different concentrations of colistin sulphate. * 
p≤0.05, ** p≤0.01 
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4.9.2 Bicarinalin 
Image A shows the control sample used. From image B to E the peptide concentration 
increases by 10 fold and the images indicate a significant decrease in biofilm especially 
in image E. 
Using the BITPLANE Imaris software the biofilm bio-volume was quantified at four 
concentrations of Bicarinalin, 1, 10, 100, 1000 µg/ml; the results are shown in Figure 
4.9.4. The control had a bio-volume of 227,067 µm3 with a deviation of 8,668 µm3. At 
1µg/ml and 10µg/ml there was no significant difference from the control (p>0.05). At 
100µg/ml the bio-volume was 184,097 µm3 (p≤0.05). This decreased to 119,947 µm3 
at 1000 µg/ml (p≤0.01). This represented a bio-volume reduction of nearly 50%. 
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Figure 4.9.3- CLSM images: A. baumannii biofilms after being subjected to bicarinalin; grown for 24 hour in a chambered cover glass then subjected to a specific 
concentration of bicarinalin for 24 hours. Biofilms were stained with SYTO 9 for visualisation. Bicarinalin concentration in image A) Control (no peptide) B) 1 
µg/ml, C) 10 µg/ml, D) 100 µg/ml, E) 1000 µg/ml.
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Figure 4.9.4-Bio-volume (µm3) of biofilm at different concentrations of bicarinalin. * p≤0.05, ** 
p≤0.01 
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4.9.3 BP100 
Image A shows the control sample used. From image B to E the peptide concentration 
increases by 10 fold in each picture and the images indicate a very significant decrease 
in biofilm especially in images D and E. 
Using the BITPLANE Imaris software the biofilm bio-volume was quantified at four 
concentrations of BP100, 1, 10, 100, 1000 µg/ml; the results are shown in Figure 4.9.6. 
The control had a bio-volume of 227,067 µm3.with a deviation of 8,668 µm3. At 1µg/ml 
and 10µg/ml there was no significant difference from the control (p>0.05). At 
100µg/ml the bio-volume was 129,225 µm3 (p≤0.05). This decreased to 104,257 µm3 
at 1000 µg/ml (p≤0.01). This represented a bio-volume reduction of nearly 55%. 
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Figure 4.9.5- CLSM images: A. baumannii biofilms after being subjected to BP100; grown for 24 hour in a chambered cover glass then subjected to a specific 
concentration of BP100 for 24 hours. Biofilms were stained with SYTO 9 for visualisation. BP100 concentration in image A) Control (no peptide) B) 1 µg/ml, C) 10 
µg/ml, D) 100 µg/ml, E) 1000 µg/ml.
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Figure 4.9.6- Bio-volume (µm3) of biofilm at different concentrations of BP100. * p≤0.05, ** 
p≤0.01 
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5 Discussion of Results and Recommendations 
The primary objective of this research was to visualise the action of two potentially 
therapeutic antimicrobial peptides, bicarinalin and BP100, against A. baumannii cells 
and biofilms and compare their activity with the current treatment of last resort, 
colistin sulphate, using microbiological assays and microscopes.  
The MIC and MBC for the three peptides against planktonic A. baumannii cells were 
determined. The data were used in AFM analysis to visualise and quantify 
transformations in cell surface and shape, exerted by increasing peptide 
concentrations.  
The MBIC and biofilm removal assays quantified the effects of peptides on the 
formation of A. baumannii biofilms and the removal of pre-formed biofilms. The 
consequence of peptide action on the biofilm was imaged with SEM and CLSM. The 
CLSM was also used to quantify the changes in bio-volume of the biofilm with 
increasing peptide concentration. 
 
5.1 The Identification and Growth of A. baumannii 19606 
5.1.1 Identification 
Gram-staining, the API 20NE test and the oxidase test were carried out to confirm the 
identity of A. baumannii. The results of these tests are described in Section 4.1. The 
colony morphologies, as described in Table 4.1.1, are similar to those described in Peleg 
(2008). The results of the API20NE and oxidase tests (Section 4.1.4) identified, with 
99.9% certainty, the presence of the A. baumannii/calcoaceticus complex (Figure 
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4.1.8); the complementary 44°C test indicated the presence of A. baumannii species 
(Saugar et al., 2006; Vaneechoutte et al., 2011).  
The A. baumannii complex members are indistinguishable from each other using 
phenotypic methods such as those used in this project: Gram-staining, API 20NE test 
and colony morphology. Molecular and genotypic methods, such as 16S rRNA, rpoB 
gene sequencing and MALDI-TOF MS (matrix assisted laser desorption ionisation-time 
of flight mass spectrometry), can be used if required to differentiate between the 
species of this complex. (Toh et al., 2015; Dortet,et al., 2006; Schumann and Pukall, 
2013). 
The API 20E test may also be used in the identification of A. baumannii complex as, 
although it is not a member of the Enterobacteriaceae family, it is a non-fastidious Gram 
negative bacterium (Djeribi, et al., 2012; The Global Health Network, 2013). 
The results of the three phenotypic tests strongly suggest that the A. baumannii 
complex was identified including the presence of A. baumannii species. The specific 
strain A. baumannii 19606 could not be confirmed from these diagnostic tests. The 
scope of this project required confirmation of genus and species but not of the strain. 
 
5.1.2 Growth Curves 
It was essential that each experiment was performed at the same stage in the bacterial 
growth curve to establish effective quantitative comparisons between different 
peptides at varying concentrations. A growth curve for A. baumannii 19606 was 
created to investigate the viable cell count (CFU/ml) within a solution of TSB by 
measuring the absorbance of the solution at 590nm. The number of CFUs and 
absorbance at 590nm was also measured at each time interval to ensure a reliable 
calibration between CFU/ml and absorbance. For each experiment, the initial CFU/ml 
130 
was confirmed by the spread plate method. This information was used at the start of 
every experiment to ensure an initial standard CFU/ml. The results are shown in 
Section 4.2. An absorbance of 0.01 was determined to be equal to approximately 1x107 
CFU/ml; the solution was then diluted to ensure the standard cell density of 5x105 
CFU/ml. 
It was intended that the growth curve would determine the lag phase, log phase and 
stationary phase of A. baumannii growth (Figure 5.1.2). The lag and log phases were 
established but the experiment was not conducted for long enough to conclusively 
determine the stationary phase. Figure 4.4.2 shows the plateauing of CFU/ml after 26 
hours but no plateauing was seen in Figure 5.1.1.  
For this project, it was important to identify the start and duration of the log phase. The 
results obtained (Figure 5.1.1) indicated that an overnight incubation of 10-15 hours 
ensured the bacteria were in the log phase of growth. 
Subsequent experiments were commenced when the bacteria were in log phase to be at 
their optimum rate of growth. Determining the stationary phase was not essential for 
the scope of this project as the length of time A. baumannii spent in log phase was in 
excess of 30 hours which meant that overnight incubation was acceptable for the 
experiments (Fernando and Kumar, 2012). 
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Figure 5.1.1 Graph showing the absorbance of A. baumannii culture in TSB cover 30 
hours. Results from all three test samples are used to construct the standard deviation 
bars at each hour. Figure as shown in Section 4.2. 
 
The Time-Absorbance curve constructed in this project (Figure 5.1.1) is similar to that 
of Fernando (2012) which was undertaken for 16 hours. In Fernando (2012) the lag 
phase lasted for about 1.5 hours and no stationary phase was found within 16 hours. 
Further repeats could be performed to obtain a smoother curve and the experiment 
could be carried out for longer to determine the stationary phase. At the start of all 
subsequent experiments, the absorbance at 590nm was verified to be 0.01 and spread 
plate confirmed the inoculum of approximately 1x107CFU/ml. There was therefore a 
high degree of confidence that the initial inoculum used was approximately 1x107 
CFU/ml for each experiment. 
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5.2 Comparison of Peptide Treatment on Planktonic Cells of 
A. baumannii 
5.2.1 Microbiological Assays 
The MIC and MBC were determined to compare the bacteriostatic and bactericidal 
activity of three antimicrobial peptides: colistin sulphate, bicarinalin and BP100. The 
methodology used was adapted from that described by Eucast (2003) and Wiegand 
(2008). These results were used in the AFM analysis to produce images and determine 
the surface roughness and surface area of single A. baumannii cells at different peptide 
concentrations in relation to the MBC. The methodology is described in Sections 3.9, 
3.10 and 3.14 and the results in Sections 4.3, 4.4 and 4.7. 
Against planktonic A. baumannii cells, colistin sulphate had the lowest MIC and MBC 
concentration of 0.5µg/ml; this was less than bicarinalin and BP100 which both had 
MIC and MBC concentrations of 4µg/ml.  
Due to the two-fold serial dilution method applied, the recorded MIC and MBC 
concentrations are considered as a maximum since the true values could be between 
the recorded MIC/MBC concentration value and the next lowest concentration. For 
example, colistin sulphate had a MIC of 0.5 µg/ml, recorded for the first clear well. The 
MIC therefore lies between 0.25 µg/ml (turbid well) and 0.5 µg/ml (clear well). The 
MIC and MBC for bicarinalin and BP100 were identical and between 2 µg/ml and 4 
µg/ml using this methodology. The maximum value of the MIC and MBC is therefore 
reported in this thesis. 
It is likely that that the MBC would be greater than the MIC with more detailed analysis. 
A more accurate MIC and MBC could be determined by testing the concentration of 
peptide, within the two-fold dilution range to investigate any differences between the 
133 
MIC and MBC, and between bicarinalin and BP100. For this project, the recorded MIC 
and MBC values were considered sufficiently accurate for atomic force microscope 
analysis. 
The A. baumannii 19606 susceptibility to colistin sulphate obtained in this project was 
similar to those in Li (2006) who showed A. baumannii 19606 had a MIC range of 0.25-
2 µg/ml. This value of the MIC also confirms that the A. baumannii 19606 strain is 
colistin sulphate susceptible as defined by The Clinical and Laboratory Standards 
Institute (Li et al., 2006). Saugar (2006) also confirmed A. baumannii 19606 strain is 
colistin sulphate susceptible. 
The results for the MIC and MBC for bicarinalin against A. baumannii 19606 were 
compared with those of Rifflet (2012) and Téné (2014) who investigated other 
bacterial species of Cronobacter, Enterobacter and Staphylococcus. The results suggest 
that A. baumannii is more susceptible to bicarinalin compared with Cronobacter 
sakazakii (MIC: 12.8 µg/ml, MBC: 13.5 µg/ml), Enterobacter cloacae (MIC: 22.8 µg/ml, 
MBC: 45.1 µg/ml), Enterobacter aerogenes (MIC: 20.4 µg/ml, MBC: 40.7 µg/ml) and 
Staphylococcus aureus (MIC: 6-6.5 µg/ml). However, A. baumannii is not as sensitive as 
Staphylococcus xylosus (MIC: 1 µg/ml) to bicarinalin. 
The results for the MIC and MBC for BP100 against A. baumannii 19606 were similar to 
the activity of BP100 against other bacteria when compared with previous studies: 
Escherichia coli (MIC:2.84 µg/ml, MBC:4.26±0.852 µg/ml), Klebsiella pneumonia 
(MIC:1.42 µg/ml, MBC-4.97±0.71 µg/ml), Pseudomonas aeruginosa (MIC: 11.36 µg/ml, 
MBC:11.36 µg/ml), Pseudomonas syringae (MIC:3.55±7.1 µg/ml), Xanthomonas 
axonopodis (MIC:7.1-10.65 µg/ml) and Erwina amylovora (MIC:3.55-7.1 µg/ml) 
(Torcato et al., 2013; Badosa et al., 2007; Alves et al., 2010).  
134 
The MIC and MBC experiments showed that against A. baumannii 19606, colistin 
sulphate had bacteriostatic and bactericidal activity at a lower concentration compared 
to bicarinalin and BP100. 
 
5.2.1.1 Efficacy of Peptides with Regard to Structure 
All three peptides tested exhibit amphipathicity within their structure as shown in 
Sections 2.4.4, 2.4.5 and 2.4.6. Amphipathicity is a characteristic of antimicrobial peptides 
and enable their interaction with the phospholipid bilayer of the bacterial membranes 
(Laverty et al., 2011; Wadhwani et al., 2014; Rifflet et al., 2012; Velkoy et al., 2010). 
Colistin sulphate has the lowest MIC in terms of weight at 0.5 µg/ml and moles of peptide 
required at 0.43 µmol/l. Cyclic peptides have been found to generally have higher efficacy 
than linear peptides such as bicarinalin and BP100 (Hoo, 2012). 
Bicarinalin has the highest molecular weight at 2213.78 g/mol of the peptides tested 
with colistin sulphate weighing 1155.4 g/mol and BP100 weighing 1420 g/mol. 
Compared to BP100, bicarinalin has a lower MIC value in terms of its mole concentration 
at 1.8 µmol/l than BP100 at 2.8 µmol/l to inhibit bacterial growth. This indicates less 
moles of bicarinalin are required to exert the same inhibitory effect on A. baumannii than 
BP100. A factor could be the length of bicarinalin with 20 amino acids compared to 11 
amino acids in BP100 potentially enabling it to traverse the phospholipid bilayer which 
BP100 is unable to do. BP100 thus may require a higher threshold concentration to 
permeabilise the membrane assuming the carpet model mechanism (Wadhwani et al., 
2014; Tene et al., 2014; Rifflet et al., 2012). 
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5.2.2 Visualisation and Quantification of Peptide Treatment using the 
Atomic Force Microscope 
The effect of peptide activity on A. baumannii was visualised by AFM using previously 
described methods (Alves et al., 2010; Domingues et al., 2014). The images for each of 
the three peptides clearly show that, below the peptide MBC, the coccus-bacillus cell 
shape is conserved; at concentrations at and above the MBC, the cell surface, shape 
conformity and size are drastically affected (Section 4.7). 
Membrane disruption caused by peptide activity is noted from various studies (Li et al., 
2007; Braga and Ricci, 1998; Stukalov et al., 2008; Alves et al., 2010; Soon et al., 2009, & 
2011; Domingues et al., 2014). In this research project, indentations and pores are seen 
in the bacterial surface with resulting cytoplasmic leakage and debris. Some cells show 
a decrease in height and deflation, possibly due to a loss of turgor pressure (Dickson et 
al., 2015). As the peptide concentration increased, more intense membrane 
perturbation and cytoplasmic leakage were visualised. Similar observations were 
described by Li et al.(2007). 
The membrane disruption was confirmed by the quantification of the surface 
roughness and surface area. The surface roughness data from all three peptides (Figure 
5.2.1) showed that there was no statistical difference between the control and at ½ 
MBC. For colistin sulphate and bicarinalin, there was a significant increase in roughness 
at the MBC. This increase in surface roughness has been previously recorded when 
bacterial cells are subjected to antibacterial peptide activity (Sharma et al., 2003; 
Domingues et al., 2014; Alves et al., 2010). Alves (2010) found a significant increase in 
bacterial roughness at the MIC concentration of BP100 against Escherichia coli, 
consistent with the results of this project. 
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For colistin sulphate and bicarinalin, the roughness decreased at 2x MBC. This decrease 
is likely to be due to the membrane collapsing (Dickson et al., 2015). 
The results are less clear for BP100 as the error bars show a big variance in the data 
set. Further repeats would be recommended to obtain a more statistically valid data set 
to determine if the trend follows that of colistin sulphate and bicarinalin. 
The surface area data (Figure 5.2.2) also supported the observation that the cells 
shrunk as peptide concentration increased above the MBC and these results were 
consistent for all three peptides. At ½ MBC, the cell surface area increased compared to 
the control. This is believed to be because, at this concentration, normal cellular 
functions and mechanisms were still able to function, including binary fission (Reeks et 
al., 2005) . Most of the images analysed at this concentration showed elongated cells 
during the process of cell division resulting in an increased surface area (Robert, 2015). 
Due to the size of the data set, most of the cells at this concentration were in the 
process of division. The control sample data set was larger as it was carried out twice 
so selected images showing single cells could be chosen. At all other concentrations, 
data collection was carried out once so a smaller data set was obtained. 
At the MBC, although there was greater data variance, the average cell area was 
significantly less than at ½ MBC, although broadly similar to the control. Doubling the 
MBC showed a significant decrease in surface area evident in the images obtained for 
all peptides. The results indicated that it required a concentration above the MBC for 
the cells to shrink.  
Five cells at each concentration for each peptide were quantified for the surface 
roughness and surface area. Further repeats should be carried out to image more cells 
and increase the statistical accuracy of the data set. Further samples would also reduce 
the skew in the surface area data at ½ MBC as more single cells could be found, imaged 
and measured.  
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Although imaging bacterial cells in air is a widely used technique (Alves et al., 2010; 
Domingues et al., 2014; Webb et al., 2011), it can lead to dehydration of the cell and 
changes in the cell surface that were not directly caused by peptide activity. The AFM 
does allow the imaging of cells in their natural physiological conditions such as in 
broth. This is discussed in Section 2.5.1 and further in 5.6.2. 
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Figure 5.2.1- Surface roughness with increasing peptide concentrations. Tests subjected for 2 hrs 
compared to the control. * denotes p ≤0.05; ** p≤0.001. Results from sections 4.7.1, 4.7.2, 4.7.3. 
 
 
Figure 5.2.2- Surface area with increasing peptide concentrations. Tests subjected for 2 hrs 
compared to the control. * denotes p ≤0.05; ** p≤0.001. Results from sections 4.7.1, 4.7.2, 4.7.3.
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5.3 Comparison of Peptide Treatment on A. baumannii Biofilms 
5.3.1 Minimum Biofilm Inhibitory Concentration (MBIC) 
The minimum biofilm inhibitory concentration (MBIC) is defined as the lowest concentration of 
antimicrobial peptide that caused 90 % inhibition of A. baumannii biofilm formation. Using 
methods similar to those described by Gopal et al (2014), as shown in Section 3.12, biofilm 
formation was quantified using the crystal violet stain method; the results are shown in Section 
4.5. 
A twofold dilution method was used to estimate the MBIC as for the MIC and MBC. The results 
showed that, at the MBC for all three peptides, there was no formation of biofilm. This is 
consistent with the MIC and MBC results as, if the cells are dead at the MBC concentration, they 
would be unable to adhere, divide and produce the exopolysaccharide matrix leading to biofilm 
formation (Wiegand et al., 2008). 
The recorded MBIC for colistin sulphate was 0.5 µg/ml; the actual MBIC value will be between 
0.25 µg/ml and 0.5 µg/ml as biofilm formation may still occur at a lower concentration than the 
recorded MBIC. A more accurate MBIC could be determined by testing the concentration of 
peptide, within the two-fold dilution range. 
 
5.3.2 Biofilm Removal Assay 
The methodology is described in Section 3.12 and is similar to those described by Dosler (2014) 
and Song (2015). The results are shown in Section 4.6 and shown below in Figure 5.3.1. The 
results indicate that bicarinalin is superior at eradicating A. baumannii biofilms than colistin 
sulphate above its MBC and both bicarinalin and BP100 were better at concentrations above 
128 µg/ml.  
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Colistin sulphate removal activity was better at low concentrations; this was as expected due to 
its lower MBC which is nearly an order of magnitude less than bicarinalin and BP100. However, 
the maximum biofilm removed was only 52% at 512 µg/ml. 
Bicarinalin was the most effective between 8 µg/ml, where it removed 39%, to 128 µg/ml, 
where it eradicated 70% of the biofilm. A further concentration increase had no additional 
apparent effect on the biofilm. 
The removal activity of BP100 started slowly and at 16 µg/ml it had removed 20% of the 
biofilm, half that of colistin sulphate. Above 16 µg/ml BP100 increased linearly to exceed 
bicarinalin activity above 512 µg/ml. At 2048 µg/ml, the highest concentration tested, BP100 
had eradicated 94% of the biofilm. 
It is not known whether the cells within the biofilm are living or dead as the analysis is testing 
simply the presence of the total biofilm. Further research, involving the minimum biofilm 
eradication concentration (MBEC) method, is recommended (Section 5.6.1). 
Colistin sulphate had the most biofilm removal activity, as expected, at low concentrations of 1-4 
µg/ml, below the bicarinalin and BP100 MBC. Bicarinalin was the best between 8 to 128 µg/ml 
and BP100 was the most effective from 256 to 2084 µg/ml. The superior performance of 
bicarinalin, and particularly that of BP100, was not anticipated especially considering the MBC 
is nearly ten times that of colistin. 
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Figure 5.3.1- Biofilm removed (%) after being exposed to the three peptides: colistin sulphate, bicarinalin and BP100. Figure reproduced from section 
4.6.
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5.3.3 Visualisation and Quantification of Peptide Treatment using the 
Scanning Electron Microscope 
The SEM has been widely used to image bacterial biofilms (Alhede et al., 2012; Djeribi 
et al., 2012;). The images revealed, with increasing concentrations of peptide, 
progressive changes in cellular shape and structure of the biofilm (Section 4.8). 
The images only showed the surface layer of the biofilm and not the formation of 
protruding micro-colonies (Gaddy et al., 2009). 24 hours were allowed for the 
formation of a biofilm, which may not be sufficient for the extensive formation of 
micro-colonies (Gaddy et al., 2009; McConnell et al., 2013). 
Time-growth studies, further described in Section 5.6.1, would add to the 
understanding of the growth of A. baumannii biofilms. Another factor impacting biofilm 
growth could be due to the rotating conditions of 140rpm that were used. This rotation 
may have inhibited the formation of thick biofilms (Merritt et al., 2011). Further 
experiments could include a comparison of biofilm growth in static conditions and 
rotating conditions. SEM images could be made of biofilms during the time studies as 
described in Section 5.6.1. 
Membrane protrusions between bacterial cells were seen in the control sample and at 
1µg/ml concentrations for each peptide. Pili or cellular filaments between cells have 
been previously documented within biofilms (Gaddy et al., 2009; Eaktasang et al., 
2013). At the higher concentrations of 10 µg/ml and 100 µg/ml, these protrusions 
were not visible suggesting the inability of the cells to form pili at these peptide 
concentrations (Longo et al., 2014; Gaddy et al., 2009). 
The effect of the peptides on the cells within the biofilm caused cell shrinkage, severe 
disruption to membrane and cellular conformity along with cytoplasmic leakage and 
debris. These changes were also visualised in the AFM images.  
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The 1000 µg/ml sample for each of the peptides were not visualised due to the time 
constraint of viewing all samples within the 8 hour period at the Electron Microscopy & 
Spectroscopy Centre at the University of Leeds. At this concentration, there is likely to 
be extensive or complete cell lysis. Figure 5.3.2 illustrates the effect of bicarinalin at 100 
µg/ml and at this concentration most of the cells are lysed. The higher magnification 
images only show a small sector of the biofilm and the inset image, at 5,000x 
magnification displays a larger area of the biofilm. 
 
Figure 5.3.2- SEM images of A. baumannii biofilms subjected to 100 µg/ml Bicarinalin for 
24 hours. Biofilms grown on polystyrene pegs for 24 hours. 30000x magnification. 
Insert magnification 5000x. Figure reproduced from section 4.8.2. 
 
5.3.4 Visualisation and Quantification of Peptide Treatment using the 
Confocal Laser Scanning Microscope 
The method and preparation for CLSM visualisation is described in Section 3.16 and is 
similar to methodologies previously used (Innovotech Inc., 1996; Yerly et al., 2007; 
Harrison et al., 2006). In this project, BacLight stain containing SYTO9, was applied to 
the A. baumannii biofilms to visualise and quantify the biofilm bio-volume with 
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increasing concentrations of peptide. The method was similar to that described by 
Harrison (2006).  
The CLSM images (Section 4.9), showed a decrease in biofilm as the peptide 
concentration increased. This was quantified by calculating the bio-volume using 
BITPLANE Imaris software.  
Bio-volume was chosen to be quantified as it best represented the change in biofilm as 
the peptide concentration increased. Other biofilm characteristics may also be 
quantified such as biofilm roughness, by a root-mean-squared calculation, as described 
in the quantification of surface roughness in the AFM images (Section 4.7). Average 
biofilm thickness could be assessed by measuring the depth of the biofilm from the 
surface at multiple points on the biofilm and averaging the values. The maximum 
thickness could also be determined by measuring the depth of the biofilm from the 
surface level to the highest point. All these measurements would quantify the effect of 
peptide activity on the biofilm. 
Biofilms at each of the four peptide concentrations were visualised and quantified 
(Section 4.9). The error bars for some of the results were wide especially for BP100. 
Five different areas of the biofilm were analysed for each peptide at each concentration. 
The results are very dependent on the samples analysed, are semi quantitative and 
measure dead as well as living biofilms. The experiment was only carried out once so 
has a high variance in the results. It is recommended that further repeats are carried 
out to obtain a larger set of statistically robust data and to validate the accuracy of the 
results obtained in this project. However, with the results discussed in Section 4.9, the 
following conclusions may be drawn. The trends are consistent to those obtained by the 
biofilm removal assay described in Section 4.6 (and summarised in Figure 5.3.1) which 
is encouraging and indicates a confidence in the methodologies and results. 
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With increasing concentration of colistin sulphate from 10 and 100 µg/ml, there was a 
progressive reduction in bio-volume. There was no noticeable reduction above 100 
µg/ml consistent with the results in Figure 5.3.1. The maximum bio-volume reduction 
compared with the control was approximately 25%. 
With bicarinalin, the biofilm reduction was immediate from 1 µg/ml and increased to 
the maximum concentration tested of 1000 µg/ml. At concentrations higher than 1000 
µg/ml, the peptide performed better than colistin sulphate with a 50% biofilm 
reduction compared to 25%. 
The results for BP100 showed at high concentrations (>100 µg/ml) the peptide was 
more effective than bicarinalin and colistin. At 1000 µg/ml the biofilm reduction was 
55% compared with only 25% for colistin.  
The results were very encouraging and showed a similar trend to those obtained from 
the biofilm removal assay described in Section 5.2.1. They indicate that both bicarinalin 
and BP100 are more effective than colistin sulphate against A. baumannii biofilms 
especially at high concentrations. 
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5.4 Significance of the Results 
The results indicate that bicarinalin and BP100 both have similar bactericidal and 
generally better biofilm activity against A. baumannii than colistin sulphate, an 
antibiotic currently used as a ‘last resort’ treatment (Karageorgopoulos and Falagas, 
2008). At all concentrations (>MBC) bicarinalin is more effective at removing A. 
baumannii biofilms than colistin sulphate. At concentrations at and above 128 µg/ml, 
BP100 is more effective against A. baumannii biofilms than colistin sulphate. At the 
highest concentrations tested (2048 µg/ml), BP100 is even more effective than 
bicarinalin and is twice as effective as colistin sulphate. Cytotoxic studies, as described 
in Section 5.6.1, will determine whether, at these concentrations, bicarinalin and BP100 
can be used in clinical treatment. 
The results support the hypothesis that AMPs, like bicarinalin and BP100, could be 
used in the treatment of biofilms (Dawgul et al., 2014). Colistin sulphate performs well 
against single cells but significantly less well against the biofilms. Colistin sulphate 
against P. aeruginosa has been shown to have a MIC concentration of 0.25-2 µg/ml and 
a MBC concentration of 0.5-2 µg/ml. This increased to 160-2560 µg/ml when tested 
against biofilms, a 320-1280% increase (Dosler and Karaaslan, 2014). A baumannii is 
able to form biofilms so it is essential that future tests to investigate peptide efficiency 
are performed on bacterial biofilms. The results of both bicarinalin and BP100 against 
biofilms are therefore extremely significant and encouraging.  
 
5.5 Additional research 
Additional research should be carried out to verify the accuracy and reliability of the 
results obtained in this project. 
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The biofilm removal assay (Sections 3.13 and 4.6) was carried out twice in triplicate. 
This should be repeated at least once more to obtain more statistically robust results. 
Five cells were imaged and measured for each peptide and concentration using AFM 
(Sections 3.14 and 4.7). Further repeats to obtain a larger data set for each 
concentration and peptide should be made.  
For the SEM analysis (Sections 3.15 and 4.8), the 1000 µg/ml for each peptide was not 
imaged due to the time constraint at the University of Leeds. This concentration should 
be visualised. 
The CLSM investigation was carried out once (Sections 3.16 and 4.9). This should be 
repeated at least a further two times until statistically robust results are obtained.  
 
5.6 Further Research 
Further research, using microbiological assays and AFM, SEM and CLSM, can be carried 
out to gain a comprehensive understanding of A. baumannii biofilm growth and peptide 
activity on single cells and biofilms. 
 
5.6.1 Microbiology Assays 
Further research should be carried out to understand more about A. baumannii biofilm 
growth in different conditions and timescales. Biofilms grown in static conditions and a 
range of rotating frequencies will help determine the optimum conditions in which 
they form. 
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A recommended timescale experiment is to investigate how quickly a peptide exerts its 
activity on planktonic cells and preformed biofilms (Vila-Farres et al., 2011). The 
following techniques are recommended: 
1. Planktonic Cells- Concentrations of peptides at 1xMIC, 2xMIC, 4xMIC and 8xMIC 
could be added to 10ml aliquots of A. baumannii at 5x105 CFU/ml and 
incubated. Samples would then be taken at time intervals such as 0, 4, 7, 24, 48 
hours, the peptide neutralised and the solution spread onto an agar plate and 
colonies counted after incubation. A reduction of 3 log10 CFU/ml compared to 
the initial inoculum would be considered bactericidal.  
2. Biofilm-A preformed biofilm, grown for a defined length of time, using data 
from the biofilm growth curve, is formed in the 96 well plates. A specified 
concentration of peptide, possibly derived from the MBEC experiment (as the 
concentration is known) will kill all the cells in the biofilm. The peptide would 
be incubated with the biofilm for periods such as 0.5, 1, 2, 4, 12, 24, 24 hours. At 
the specified time, the biofilms would be washed with a neutraliser to inhibit 
any further peptide activity. Crystal violet stain will quantify the remaining 
biofilm using CLSM. 
 
The construction of accurate biofilm growth curves could be made. The quantity of 
biofilm presence can be measured by crystal violet, similarly to the MBIC method and 
quantification of biofilm removal experiments. Time intervals such as at 0.5, 1, 6, 12, 
24, 48 hours can be investigated. This would help understand if biofilm constantly 
increases, if there is a plateau or if it starts to reduce after a certain length of time. For 
example, if the biofilm starts to break down after 12 hours during a 24 hours 
experiment then the decrease in biofilm would not be completely due to peptide 
activity (Vila-Farres et al., 2011). This will help to decide the optimum time to add a 
peptide, before a potential decrease in biofilm. 
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The minimum biofilm eradication concentration (MBEC) is a widely used technique to 
determine the concentration of peptide required to kill all bacterial cells within a 
biofilm (Olson et al., 2002; Ceri et al., 1999; Feng et al., 2013; Dosler and Karaaslan, 
2014; Marumo et al., 2013). This experiment is a refinement of the MBIC experiment as 
it measures the eradication or death of cells within the biofilm. Biofilms are grown on 
the polystyrene pegs, such as the plate pegs used in this project for SEM visualisation. 
The biofilms are then subjected to a twofold dilution of peptide. The pegs are then 
ultra-sonicated and incubated. The lowest concentration, where no regrowth was 
observed, is recorded as the MBEC. This investigation could follow the biofilm removal 
experiment (Section 3.13). 
Using the methods described in this project, other antimicrobial peptides could be 
tested against A. baumannii cells and biofilms. Additional peptides that may be 
considered for a project include haloganan (Shin et al., 2014), pleurocidin (Souza et al., 
2013), and alyteserin 1c (Subasinghage, et al., 2011). 
In this project, the colistin sulphate susceptible A. baumannii strain 19606 was used. 
AMPs should be tested against multi-drug resistant A. baumannii strains. Strains such as 
A. baumannii 208628 and 201630, are known to be colistin sulphate resistant and 
should be investigated (Saugar et al., 2006). 
Bicarinalin and BP100 could be tested against other clinically relevant bacteria such as 
the Gram negative Klebsiella pneumonia and Pseudomonas aeuroginosa and the Gram 
positive bacteria Staphylococcus aureus, Enterococcus faecalis and Streptococcus 
gordonii (Rice, 2008; Boucher et al., 2009).  
After determining the MBEC and MBC for each peptide, cytotoxic studies should be 
carried out. Human erythrocytes or keratinocytes could be used (Feng et al., 2013; 
Rifflet et al., 2012). This will highlight the potential of these two AMPs for use in 
systemic medical treatment by their ability not to kill eukaryotic cells at bactericidal 
concentrations. 
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5.6.2 Atomic Force Microscope 
One to five cells were imaged during one session of about 2-3 hours. This meant that 
cells imaged at the end of the session may have evolved a slightly different 
topographically compared to the cells imaged at the start. One way to counter this 
would be to analyse the cells under their natural physiological conditions such as liquid 
broth and a controlled temperature and potentially to visualise the morphological 
alterations on the bacterial cell surface exposed to the peptides as they occur (Braga 
and Ricci, 1998; Doktycz et al., 2003).  
The mechanical and adhesive properties of bacterial cells can be investigated by 
measuring force-distance curves. This measures the interaction of forces between the 
AFM tip and bacterial cells and its cell wall components with a high resolution of tens of 
pico-newtons. This, in principle, would allow the determination of the turgor pressure 
within the bacterial cell (Stukalov et al., 2008).  
 
5.6.3 Scanning Electron Microscope 
The SEM could be used to visualise biofilms grown for different timescales or subjected 
to AMPs for different timescales as proposed in Section 5.6.1. 
 
5.6.4 Confocal Laser Scanning Microscope 
The CLSM can be used with the SEM to visualise and quantify biofilm growth, by bio-
volume and other parameters such as roughness and thickness, during the time studies 
of A. baumannii biofilm growth, as suggested in Section 5.6.1. 
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SYTO9 is often used in tandem with another nucleic stain propidium iodide (PI). PI is a 
nucleic acid membrane impermeable stain and only stains cells with a disrupted 
membrane. As it has a higher affinity for nucleic acid it will displace the SYTO9 stain 
and these cells would fluoresce red. In theory, cells that fluoresce green with SYTO9 are 
alive and cells that fluoresce red with PI are dead. Using different excitation and 
emission ranges for each of the stains it is possible to different between the two. This 
would enable the quantification of live and dead cells within a population or biofilm 
(Stocks, 2004; Harrison et al., 2006). 
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6 Conclusions 
6.1 Project Objectives 
This project investigated the opportunistic pathogen A. baumannii, responsible for 
various infections such as pneumonia, septicaemia, wound infections and meningitis. It 
is clinically important due to its ability to become rapidly resistant to a wide range of 
antimicrobials and also to persist on clinical surfaces by forming biofilms.  
Acinetobacter baumannii is the most clinically relevant species of the Acinetobacter 
genus and, due to the emergence of MDR strains; it is recognised as a major 
opportunistic pathogen by its inclusion as a member of the ‘ESKAPE’ group. 
 Recent novel antibiotic classes have been limited to the treatment of Gram-positive 
infections while it is the Gram-negative infections, caused by pathogens such as 
Pseudomonas aeruginosa, Enterobacteriaceae, and A. baumannii, that are in most 
urgent need of new therapies. 
The objective of this research was to compare and visualise the activity of two 
potentially therapeutic antimicrobial peptides, bicarinalin and BP100, with the 
currently used colistin sulphate, against A. baumannii. The activity of the peptides 
against planktonic cells and biofilms of A. baumannii were investigated both 
quantitatively and qualitatively using microbiological assays and microscopes.  
 
6.2 Project Results 
The A. baumannii genus and species was verified (Section 4.1). However, the specific 
strain A. baumannii 19606 could not be confirmed from these diagnostic tests which 
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were outside scope of the current project. Ribotyping and MALDI-TOF MS could be 
carried out to identify a specific strain (Section 5.1). 
The MIC and MBC experiments showed that, for planktonic cells of A. baumannii, 
colistin sulphate had bacteriostatic and bactericidal activity at a lower concentration 
compared to bicarinalin and BP100 (Sections 4.3 and 4.4). The effect of peptide activity 
on individual cells of A. baumannii was visualised by the AFM. The images for each of 
the three peptides clearly showed that, below the MBC, the coccus-bacillus cell shape is 
conserved; at concentrations at and above the MBC, the cell surface, conformation and 
size are drastically affected (Section 4.7). 
The surface area and roughness data, measured by the AFM, also supported the 
observation that the cells shrunk as peptide concentration increased above the MBC 
and these results were consistent for all three peptides (Section 4.7).  
However, the analysis of the peptides against biofilms of A. baumannii gives 
significantly different results. The biofilm removal assay (Section 4.6) and the CLSM 
investigation (Section 4.9) show that both bicarinalin and BP100 have considerably 
better biofilm removal activity against A. baumannii biofilms than colistin sulphate at 
high concentrations above 1000µg/ml. (Section 5.3). 
In terms of biofilm removal, colistin sulphate was relatively the most effective at low 
concentrations, from 1 to 4 µg/ml, but the most it removed was approximately 50% of 
the biofilm at 512 µg/ml. Bicarinalin was relatively the most effective from 8 µg/ml to 
128 µg/ml, where it eradicated 70% of the biofilm. The biofilm removal by BP100 
started more slowly but at higher concentrations, above 128 µg/ml, it exceeded colistin 
sulphate activity and, above 512 µg/ml, it exceeded bicarinalin activity. At 2048 µg/ml, 
the highest concentration tested, BP100 eradicated nearly 95% of the biofilm (Section 
4.6).  
154 
The semi-quantitative biofilm removal tests using the CLSM also showed that 
bicarinalin and BP100 were more effective than colistin sulphate, especially at high 
concentrations (Section 4.9). At 1000 µg/ml, bicarinalin and BP100 removed 
approximately 50-55% of biofilm, twice as much as colistin.  
The effect of the peptides on the cells within the biofilm involved cell shrinking and 
severe disruption in membrane and cellular conformity. Shrinkage of the cells was also 
observed together with cytoplasmic leakage and debris with the SEM (Section 4.8).  
 
6.3 Comments on the Results 
The results support the hypothesis that potential alternative AMPs, as bicarinalin and 
BP100, could be used in the treatment of infections caused by biofilm-producing 
prokaryotes. Colistin sulphate performs well against planktonic cells but significantly 
less well against biofilms. As A. baumannii is able to form biofilms, it is essential that 
future tests investigating peptide efficiency are performed on bacterial biofilms. 
Colistin sulphate is traditionally used as an antibiotic of the last resort and has several 
adverse side effects (Section 2.4.4). The results for both bicarinalin and BP100 against 
A. baumannii biofilms are therefore considered as extremely significant and 
encouraging.  
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8 Appendices 
8.1 API 20NE Results sheet  
(The Global Health Network, 2015) 
TEST REACTION NEGATIVE POSITIVE 
NO3NO2 
NO2N2 
Reduction of 
potassium nitrate 
Colourless 
Red/pink 
Red (NIT1+NIT2) 
Colourless (Zn) 
TRP 
Indole production 
from tryptophan 
Yellow Pink 
GLU Glucose fermentation Blue/green Yellow 
ADH Arginine hydrolysis Yellow Orange/pink/red 
URE Urea hydrolysis Yellow Orange/pink/red 
ESC Aesculin hydrolysis Yellow Grey/brown/black 
GEL Gelatin hydrolysis No pigment diffusion 
Diffusion of black 
pigment 
PNPG 
p-nitrophenyl-D-
galactopyranoside 
hydrolysis 
Colourless Yellow 
GLU Glucose assimilation Transparent Opaque 
ARA 
Arabinose 
assimilation 
Transparent Opaque 
174 
MNE Mannose assimilation Transparent Opaque 
MAN Mannitol assimilation Transparent Opaque 
NAG 
N-acetyl-glucosamine 
assimilation 
Transparent Opaque 
MAL Maltose assimilation Transparent Opaque 
GNT 
Gluconate 
assimilation 
Transparent Opaque 
CAP Caprate assimilation Transparent Opaque 
ADI Adipate assimilation Transparent Opaque 
MLT Malate assimilation Transparent Opaque 
CIT Citrate assimilation Transparent Opaque 
PAC 
Phenyl-acetate 
assimilation 
Transparent Opaque 
Oxidase Cytochrome oxidase Colourless Purple 
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8.2 Maximum dilutions per hour and which dilutions being 
spread plated. 
Hour Max Dilutions  Dilutions Spread 
0 10-5 10-3,10-4, 10-5 
1 10-6 10-4,10-5, 10-6 
2 10-7 10-5,10-6, 10-7 
3 10-7 10-5,10-6, 10-7 
4 10-7 10-5,10-6, 10-7 
5 10-7 10-5,10-6, 10-7 
6 10-7 10-5,10-6, 10-7 
7 10-8 10-6,10-7, 10-8 
8 10-8 10-6,10-7, 10-8 
9 10-8 10-6,10-7, 10-8 
10 10-9 10-7,10-8, 10-9 
11 10-9 10-7,10-8, 10-9 
12 10-9 10-7,10-8, 10-9 
13 10-9 10-7,10-8, 10-9 
14 10-10 10-8,10-9, 10-10 
15 10-10 10-8,10-9, 10-10 
16 10-11 10-9,10-10, 10-11 
17 10-11 10-9,10-10, 10-11 
18 10-12 10-10,10-11, 10-12 
19 10-12 10-10,10-11, 10-12 
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20 10-12 10-10,10-11, 10-12 
21 10-13 10-11,10-12, 10-13 
22 10-13 10-11,10-12, 10-13 
23 10-13 10-11,10-12, 10-13 
24 10-14 10-12,10-13, 10-14 
25 10-14 10-12,10-13, 10-14 
26 10-14 10-12,10-13, 10-14 
27 10-14 10-12,10-13, 10-14 
28 10-14 10-12,10-13, 10-14 
29 10-14 10-12,10-13, 10-14 
30 10-14 10-12,10-13, 10-14 
 
